{
    "drugSuccessPredictions": [
      {
        "drugId": "11589",
        "displayName": "imetelstat",
        "drugPrograms": [
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Paediatric Investigation Plan",
            "startDate": "24-Nov-2015",
            "endDate": "27-Dec-2024",
            "statusDate": "29-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "92%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Nov-2015",
                "endDate": "29-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2023",
                "endDate": "16-Nov-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jul-2024",
                "predictedDateU50": "27-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, further data from the phase II/III IMerge trial (NCT02598661) were presented. Relative to the overall population subset had a lower incidence of grade >/= 3 neutropenia (66 and 54%, respectively), but a higher rate of grade >/=3 thrombocytopenia (53 and 62%, respectively). Among all, 88% had reversible liver function tests elevations by at least one grade [<ulink linkType=\"Reference\" linkID=\"2045561\">2045561</ulink>], [<ulink linkType=\"Reference\" linkID=\"2046002\">2046002</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, data from the phase II/III IMerge trial (NCT02598661) in patients with myelodysplastic syndromes were presented. Among the 38 patients, the 8-week red blood cell-transfusion independence (TI) rate was 37%. Durability of 24-week TI responses was noted, with a median duration of 10 months and the longest ongoing response of <2 years. All patients who achieved durable TI demonstrated a hemoglobin rise of >/= 3.0 g/dl compared to baseline during the transfusion-free interval [<ulink linkType=\"Reference\" linkID=\"2098353\">2098353</ulink>], [<ulink linkType=\"Reference\" linkID=\"2100955\">2100955</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, the 8-week red blood cell-transfusion independence rate in the combined cohort of 38 patients in the phase II portion of the phase II/III IMerge trial in transfusion dependent patients with low or intermediate-1 risk myelodysplastic syndromes was 42% (16/38) [<ulink linkType=\"Reference\" linkID=\"2152601\">2152601</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, data from phase II portion of phase II/III trial (IMerge) were reported [<ulink linkType=\"Reference\" linkID=\"2179341\">2179341</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, the EMA's COMP issued a positive opinion on Geron's application for Orphan drug designation for imetelstat as a potential treatment for myelodysplastic syndromes [<ulink linkType=\"Reference\" linkID=\"2294809\">2294809</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "31-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, the EMA granted Orphan drug designation for the treatment of myelodysplastic syndrome [<ulink linkType=\"Reference\" linkID=\"2307368\">2307368</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Paediatric Investigation Plan",
                "status": "Positive Opinion",
                "milestoneDate": "29-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, the EMA's Paediatric Committee adopted a positive opinion agreeing a Paediatric Investigation plan for imetelstat for AML and MDS, including juvenile myelomonocytic leukemia [<ulink linkType=\"Reference\" linkID=\"2420891\">2420891</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Jul-2022",
                "notes": "In August 2019, patient screening and enrollment in the phase III part of the IMerge trial (NCT02598661) began; it was to enroll 170 patients, with topline data expected by mid-2022 [<ulink linkType=\"Reference\" linkID=\"2181703\">2181703</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2020, topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) were expected in 2H22 [<ulink linkType=\"Reference\" linkID=\"2294809\">2294809</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In October 2022, a phase II trial (NCT05583552) was expected to be initiated December 2022 [ <ulink linkID=\"2765740\" linkType=\"Reference\">  2765740 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In August 2021, the expected timing was accelerated by 3 months to 1Q23 for topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) [ <ulink linkID=\"2512726\" linkType=\"Reference\">  2512726 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Jan-2023",
                "notes": "In October 2021, topline data from the phase III IMerge study (NCT02598661) in patients with lower risk myelodysplastic syndrome (MDS) who are relapsed or refractory to erythropoiesis-stimulating agents (ESAs) were expected at the beginning of January 2023 [ <ulink linkID=\"2550439\" linkType=\"Reference\">  2550439 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2022, the company noted that if IMerge data were positive, an MAA in Europe for lower risk MDS was expected in 2H23 [ <ulink linkID=\"2630620\" linkType=\"Reference\">  2630620 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "29-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the European Medicines Agency (EMA) accepted the filing for review for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS) [ <ulink linkID=\"3279498\" linkType=\"Reference\"> 3279498 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In August 2023, MAA for imetelstat in the EU for myelodysplastic syndrome was to be submitted in 4Q23 [ <ulink linkID=\"3045558\" linkType=\"Reference\"> 3045558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In January 2023, EU launch for lower risk MDS was expected by the end of 2024 [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "By November 2023, MAA review for lower risk MDS was expected to complete by the end of 2024 [ <ulink linkID=\"3488209\" linkType=\"Reference\"> 3488209 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "By November 2023, MAA review for lower risk MDS was expected to complete by the end of 2024 [ <ulink linkID=\"3488209\" linkType=\"Reference\"> 3488209 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Nov-2015",
            "endDate": "14-Sep-2027",
            "statusDate": "03-Mar-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Nov-2015",
                "endDate": "13-Oct-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Oct-2026",
                "endDate": "11-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Dec-2025",
                "predictedDateU50": "30-Jan-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Apr-2027",
                "predictedDateU50": "14-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, further data from the phase II/III IMerge trial (NCT02598661) were presented. Relative to the overall population subset had a lower incidence of grade >/= 3 neutropenia (66 and 54%, respectively), but a higher rate of grade >/=3 thrombocytopenia (53 and 62%, respectively). Among all, 88% had reversible liver function tests elevations by at least one grade [<ulink linkType=\"Reference\" linkID=\"2045561\">2045561</ulink>], [<ulink linkType=\"Reference\" linkID=\"2046002\">2046002</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, data from the phase II/III IMerge trial (NCT02598661) in patients with myelodysplastic syndromes were presented. Among the 38 patients, the 8-week red blood cell-transfusion independence (TI) rate was 37%. Durability of 24-week TI responses was noted, with a median duration of 10 months and the longest ongoing response of <2 years. All patients who achieved durable TI demonstrated a hemoglobin rise of >/= 3.0 g/dl compared to baseline during the transfusion-free interval [<ulink linkType=\"Reference\" linkID=\"2098353\">2098353</ulink>], [<ulink linkType=\"Reference\" linkID=\"2100955\">2100955</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, the 8-week red blood cell-transfusion independence rate in the combined cohort of 38 patients in the phase II portion of the phase II/III IMerge trial in transfusion dependent patients with low or intermediate-1 risk myelodysplastic syndromes was 42% (16/38) [<ulink linkType=\"Reference\" linkID=\"2152601\">2152601</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, data from phase II portion of phase II/III trial (IMerge) were reported [<ulink linkType=\"Reference\" linkID=\"2179341\">2179341</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2020, topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) were expected in 2H22 [<ulink linkType=\"Reference\" linkID=\"2294809\">2294809</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Jul-2022",
                "notes": "In August 2019, patient screening and enrollment in the phase III part of the IMerge trial (NCT02598661) began; it was to enroll 170 patients, with topline data expected by mid-2022 [<ulink linkType=\"Reference\" linkID=\"2181703\">2181703</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In August 2021, the expected timing was accelerated by 3 months to 1Q23 for topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) [ <ulink linkID=\"2512726\" linkType=\"Reference\">  2512726 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Jan-2023",
                "notes": "In October 2021, topline data from the phase III IMerge study (NCT02598661) in patients with lower risk myelodysplastic syndrome (MDS) who are relapsed or refractory to erythropoiesis-stimulating agents (ESAs) were expected at the beginning of January 2023 [ <ulink linkID=\"2550439\" linkType=\"Reference\">  2550439 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Oct-2026",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT02598661) in MDA was expected to complete in October 2026 [ <ulink linkID=\"1718703\" linkType=\"Reference\"> 1718703 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jan-2014",
            "endDate": "06-Jul-2024",
            "statusDate": "20-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Jan-2014",
                "endDate": "24-Nov-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Nov-2015",
                "endDate": "20-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jun-2023",
                "endDate": "02-Jun-2024",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jun-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2024",
                "predictedDateU50": "06-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, further data from the phase II/III IMerge trial (NCT02598661) were presented. Relative to the overall population subset had a lower incidence of grade >/= 3 neutropenia (66 and 54%, respectively), but a higher rate of grade >/=3 thrombocytopenia (53 and 62%, respectively). Among all, 88% had reversible liver function tests elevations by at least one grade [<ulink linkType=\"Reference\" linkID=\"2045561\">2045561</ulink>], [<ulink linkType=\"Reference\" linkID=\"2046002\">2046002</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, data from the phase II/III IMerge trial (NCT02598661) in patients with myelodysplastic syndromes were presented. Among the 38 patients, the 8-week red blood cell-transfusion independence (TI) rate was 37%. Durability of 24-week TI responses was noted, with a median duration of 10 months and the longest ongoing response of <2 years. All patients who achieved durable TI demonstrated a hemoglobin rise of >/= 3.0 g/dl compared to baseline during the transfusion-free interval [<ulink linkType=\"Reference\" linkID=\"2098353\">2098353</ulink>], [<ulink linkType=\"Reference\" linkID=\"2100955\">2100955</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, the 8-week red blood cell-transfusion independence rate in the combined cohort of 38 patients in the phase II portion of the phase II/III IMerge trial in transfusion dependent patients with low or intermediate-1 risk myelodysplastic syndromes was 42% (16/38) [<ulink linkType=\"Reference\" linkID=\"2152601\">2152601</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, data from phase II portion of phase II/III trial (IMerge) were reported [<ulink linkType=\"Reference\" linkID=\"2179341\">2179341</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In November 2021, an investigator-sponsored trial (IMpress) was planned to start in 1H22 to assess single-agent imetelast in higher-risk MDS and acute myeloid leukemia patients after failing hypomethylating agent [ <ulink linkID=\"2563899\" linkType=\"Reference\">  2563899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Jul-2022",
                "notes": "In August 2019, patient screening and enrollment in the phase III part of the IMerge trial (NCT02598661) began; it was to enroll 170 patients, with topline data expected by mid-2022 [<ulink linkType=\"Reference\" linkID=\"2181703\">2181703</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In March 2022, the phase II IMpress trial to assess single-agent imetelast in higher-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia was to start in 2H22 [ <ulink linkID=\"2630620\" linkType=\"Reference\">  2630620 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2020, topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) were expected in 2H22 [<ulink linkType=\"Reference\" linkID=\"2294809\">2294809</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2021, the company noted that if IMerge data were positive, a completed NDA for lower risk myelodysplastic syndrome was expected in 2023 [<ulink linkType=\"Reference\" linkID=\"2420665\">2420665</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Jan-2023",
                "notes": "In October 2021, topline data from the phase III IMerge study (NCT02598661) in patients with lower risk myelodysplastic syndrome (MDS) who are relapsed or refractory to erythropoiesis-stimulating agents (ESAs) were expected at the beginning of January 2023 [ <ulink linkID=\"2550439\" linkType=\"Reference\">  2550439 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In August 2021, the expected timing was accelerated by 3 months to 1Q23 for topline data from the phase III IMerge trial (NCT02598661) in patients with lower risk transfusion-dependent myelodysplastic syndromes who are relapsed or refractory to an erythropoiesis stimulating agent, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del(5q) [ <ulink linkID=\"2512726\" linkType=\"Reference\">  2512726 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In March 2022, the company noted that if IMerge data were positive, an NDA in the US for lower risk MDS was expected in 1H23 [ <ulink linkID=\"2630620\" linkType=\"Reference\">  2630620 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline data from phase III (NCT02598661; IMerge) trial in lower risk MDS were reported showing that the study met primary endpoint [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In May 2023, NDA was planned to submit to the US FDA for the treatment of lower risk MDS in June 2023 [ <ulink linkID=\"2932857\" linkType=\"Reference\"> 2932857 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "20-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, an NDA was submitted to the US FDA for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk MDS who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the positive data from phase III trial (IMerge). At that time, company requested a Priority Review from the US FDA and expected a communication regarding the acceptance of NDA for review within 60 days [ <ulink linkID=\"2983187\" linkType=\"Reference\"> 2983187 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Compassionate Use",
                "status": "Granted",
                "milestoneDate": "29-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the drug was available under an Expanded Access Protocol in the US for patients with transfusion dependent non-del(5q) lower risk MDS, who are relapsed or refractory to, or unable to use ESAs, and not previously treated with lenalidomide and HMAs [ <ulink linkID=\"2994491\" linkType=\"Reference\"> 2994491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In January 2023, an NDA submission for lower-risk MDS in the US was expected in mid-2023, based on positive IMerge data [ <ulink linkID=\"2802524\" linkType=\"Reference\">  2802524 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In March 2022, the company noted that if IMerge data were positive, launch for lower risk MDS could occur in 1H24 [ <ulink linkID=\"2630620\" linkType=\"Reference\">  2630620 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2022, US approval for lower risk MDS was expected in 1H24 [ <ulink linkID=\"2764495\" linkType=\"Reference\">  2764495 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2022, US approval for lower risk MDS was expected in 1H24 [ <ulink linkID=\"2764495\" linkType=\"Reference\">  2764495 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "16-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the US FDA assigned a standard review and a PDUFA action date of June 16, 2024, for imetelstat’s NDA for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes [ <ulink linkID=\"3046858\" linkType=\"Reference\"> 3046858 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE, FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Paediatric Investigation Plan",
            "startDate": "05-Jun-2023",
            "endDate": "12-Feb-2030",
            "statusDate": "05-Jun-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Jun-2023",
                "endDate": "15-Jun-2026",
                "successPercentage": "23%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Jun-2026",
                "endDate": "05-Jan-2029",
                "successPercentage": "29%",
                "predictedDateL50": "28-May-2025",
                "predictedDateU50": "22-Nov-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Jan-2029",
                "endDate": "01-Jan-2030",
                "successPercentage": "85%",
                "predictedDateL50": "27-Nov-2027",
                "predictedDateU50": "21-May-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Sep-2029",
                "predictedDateU50": "12-Feb-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2026",
                "milestoneExtendedDate": "30-Jun-2026",
                "notes": "In October 2022, a phase II trial (NCT05583552) was expected to be completed in June 2026 [ <ulink linkID=\"2765740\" linkType=\"Reference\">  2765740 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2015",
            "endDate": "27-Apr-2027",
            "statusDate": "12-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2015",
                "endDate": "12-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Apr-2021",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "23-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "07-Jan-2026",
                "predictedDateU50": "25-Jul-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Dec-2026",
                "predictedDateU50": "27-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR",
              " KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Apr-2021",
            "endDate": "29-Jun-2027",
            "statusDate": "12-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "12-Apr-2021",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "09-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "22-Oct-2025",
                "predictedDateU50": "09-Sep-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Jan-2027",
                "predictedDateU50": "29-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "30-Jun-2025",
                "notes": "In August 2023, interim analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H25 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2026",
                "milestoneExtendedDate": "30-Jun-2026",
                "notes": "In August 2023, final analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H26 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis was expected to complete in April 2026 [ <ulink linkID=\"2337265\" linkType=\"Reference\"> 2337265 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track",
            "startDate": "29-Oct-2012",
            "endDate": "01-Jun-2027",
            "statusDate": "11-Dec-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Oct-2012",
                "endDate": "12-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Apr-2021",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "22-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "13-Oct-2025",
                "predictedDateU50": "16-Sep-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Dec-2026",
                "predictedDateU50": "01-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, new overall survival data from the phase II IMbark trial (NCT02426086) in patients with myelofibrosis were presented. At week 24, the symptom response based on total symptom score was 19 and 3 in the 9.4 and 4.7 arms, respectively. For the 9.4 mg/kg dose the median survival was 29.9 months, the spleen response rate was of 10% and symptom response rate of 32% [<ulink linkType=\"Reference\" linkID=\"2098713\">2098713</ulink>], [<ulink linkType=\"Reference\" linkID=\"2101054\">2101054</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, median overall survival in the 9.4 mg/kg dosing arm of the phase II IMbark trial in patients with intermediate-2 or high-risk relapsed/refractory myelofibrosis was 28.1 months [<ulink linkType=\"Reference\" linkID=\"2152601\">2152601</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "30-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, the FDA granted Fast Track designation for the treatment of adult patients with Intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF, including patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera [<ulink linkType=\"Reference\" linkID=\"2199811\">2199811</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "29-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, Geron closed the IMbark trial since they believed sufficient data from the trial to support potential late-stage development in MF had been obtained; at that time, no further follow-up of remaining patients was being conducted [<ulink linkType=\"Reference\" linkID=\"2255751\">2255751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In March 2020, a proof-of-concept study to assess the drug in patients with intermediate-2 or high-risk myelodysplastic syndrome and acute myeloid leukemia was expected to start by the end of 4Q20 [<ulink linkType=\"Reference\" linkID=\"2255751\">2255751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In October 2020, a phase III trial (NCT04576156) in  intermediate-2 or high-risk Myelofibrosis was expected to initiate in March 2021 [<ulink linkType=\"Reference\" linkID=\"2337265\">2337265</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In November 2021, a phase I trial (IMproveMF) was planned to start in 1H22 to assess imetelast in combination with ruxolitinib for frontline MF patients [ <ulink linkID=\"2563899\" linkType=\"Reference\">  2563899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In March 2021, an interim analysis from the phase III IMpactMF trial (NCT04576156) in intermediate-2 or high-risk myelofibrosis was expected in 2024 and a final analysis in 2025 [<ulink linkType=\"Reference\" linkID=\"2281462\">2281462</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In May 2020, Geron expected the phase III study in intermediate-2 or high-risk myelofibrosis to start in 1Q21, to complete enrolment in 2H22, to conduct an interim analyis in 1H23 and to conduct the final analysis in 1H24 [<ulink linkType=\"Reference\" linkID=\"2281462\">2281462</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase III trial (NCT04576156) in  intermediate-2 or high-risk Myelofibrosis was expected to complete in May 2024 [<ulink linkType=\"Reference\" linkID=\"2337265\">2337265</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "30-Jun-2025",
                "notes": "In August 2023, interim analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H25 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2026",
                "milestoneExtendedDate": "30-Jun-2026",
                "notes": "In August 2023, final analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H26 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis was expected to complete in April 2026 [ <ulink linkID=\"2337265\" linkType=\"Reference\"> 2337265 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "16315",
              "name": "Geron Corp"
            },
            "indication": {
              "id": "2436",
              "name": "Myelofibrosis"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Jun-2015",
            "endDate": "23-Jun-2027",
            "statusDate": "11-Mar-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2015",
                "endDate": "11-Mar-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Mar-2021",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "04-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "05-Oct-2025",
                "predictedDateU50": "21-Sep-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Dec-2026",
                "predictedDateU50": "23-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "12-Nov-2015",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "14-Dec-2015",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, new overall survival data from the phase II IMbark trial (NCT02426086) in patients with myelofibrosis were presented. At week 24, the symptom response based on total symptom score was 19 and 3 in the 9.4 and 4.7 arms, respectively. For the 9.4 mg/kg dose the median survival was 29.9 months, the spleen response rate was of 10% and symptom response rate of 32% [<ulink linkType=\"Reference\" linkID=\"2098713\">2098713</ulink>], [<ulink linkType=\"Reference\" linkID=\"2101054\">2101054</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, median overall survival in the 9.4 mg/kg dosing arm of the phase II IMbark trial in patients with intermediate-2 or high-risk relapsed/refractory myelofibrosis was 28.1 months [<ulink linkType=\"Reference\" linkID=\"2152601\">2152601</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "29-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, Geron closed the IMbark trial since they believed sufficient data from the trial to support potential late-stage development in MF had been obtained; at that time, no further follow-up of remaining patients was being conducted [<ulink linkType=\"Reference\" linkID=\"2255751\">2255751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In May 2020, Geron expected the phase III study in intermediate-2 or high-risk myelofibrosis to start in 1Q21, to complete enrolment in 2H22, to conduct an interim analyis in 1H23 and to conduct the final analysis in 1H24 [<ulink linkType=\"Reference\" linkID=\"2281462\">2281462</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In October 2020, a phase III trial (NCT04576156) in  intermediate-2 or high-risk Myelofibrosis was expected to initiate in March 2021 [<ulink linkType=\"Reference\" linkID=\"2337265\">2337265</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In May 2020, Geron expected the phase III study in intermediate-2 or high-risk myelofibrosis to start in 1Q21, to complete enrolment in 2H22, to conduct an interim analyis in 1H23 and to conduct the final analysis in 1H24 [<ulink linkType=\"Reference\" linkID=\"2281462\">2281462</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In March 2021, an interim analysis from the phase III IMpactMF trial (NCT04576156) in intermediate-2 or high-risk myelofibrosis was expected in 2024 and a final analysis in 2025 [<ulink linkType=\"Reference\" linkID=\"2281462\">2281462</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, a phase III trial (NCT04576156) in  intermediate-2 or high-risk Myelofibrosis was expected to complete in May 2024 [<ulink linkType=\"Reference\" linkID=\"2337265\">2337265</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "30-Jun-2025",
                "notes": "In August 2023, interim analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H25 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2026",
                "milestoneExtendedDate": "30-Jun-2026",
                "notes": "In August 2023, final analysis of a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis patients relapsed/refractory to JAK-inhibitors was expected in the 1H26 [ <ulink linkID=\"3033345\" linkType=\"Reference\"> 3033345 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT04576156; IMpactMF) of imetelstat for the treatment of intermediate-2 or high-risk myelofibrosis was expected to complete in April 2026 [ <ulink linkID=\"2337265\" linkType=\"Reference\"> 2337265 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "37671",
        "displayName": "fexapotide triflutate",
        "drugPrograms": [
          {
            "company": {
              "id": "24154",
              "name": "Recordati Industria Chimica e Farmaceutica S.p.A"
            },
            "indication": {
              "id": "1241",
              "name": "Prostate hyperplasia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Feb-2012",
            "endDate": "",
            "statusDate": "06-Jan-2023",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Feb-2012",
                "endDate": "03-May-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-May-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "24420",
              "name": "Nymox Pharmaceutical Corp"
            },
            "indication": {
              "id": "276",
              "name": "Prostate tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Feb-2012",
            "endDate": "",
            "statusDate": "01-Mar-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Feb-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "24420",
              "name": "Nymox Pharmaceutical Corp"
            },
            "indication": {
              "id": "1241",
              "name": "Prostate hyperplasia"
            },
            "country": {
              "id": "EU",
              "name": "Europe (DE, DK, FR, GB, NL)"
            },
            "principalCompany": {
              "id": "24154",
              "name": "Recordati Industria Chimica e Farmaceutica S.p.A"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "25-Sep-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "DE",
              " DK",
              " FR",
              " GB",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "24420",
              "name": "Nymox Pharmaceutical Corp"
            },
            "indication": {
              "id": "1241",
              "name": "Prostate hyperplasia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Aug-2005",
            "endDate": "",
            "statusDate": "03-Mar-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Aug-2005",
                "endDate": "30-Apr-2009",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Apr-2009",
                "endDate": "03-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Mar-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "40735",
        "displayName": "dovitinib",
        "drugPrograms": [
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "202",
              "name": "Liver tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (DK)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jul-2018",
            "endDate": "13-Jan-2026",
            "statusDate": "26-Jul-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "26-Jul-2018",
                "endDate": "16-Sep-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Sep-2024",
                "endDate": "04-Nov-2025",
                "successPercentage": "91%",
                "predictedDateL50": "18-Jan-2024",
                "predictedDateU50": "23-May-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Nov-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jun-2025",
                "predictedDateU50": "13-Jan-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DK"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DK)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jan-2018",
            "endDate": "21-May-2026",
            "statusDate": "15-Jan-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "42%",
            "timeToRegistration": "2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Jan-2018",
                "endDate": "21-Jan-2025",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2025",
                "endDate": "14-Mar-2026",
                "successPercentage": "87%",
                "predictedDateL50": "10-Feb-2024",
                "predictedDateU50": "08-Jul-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Mar-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Oct-2025",
                "predictedDateU50": "21-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DK"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Apr-2019",
            "endDate": "09-Aug-2024",
            "statusDate": "22-Dec-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "91%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-Apr-2019",
                "endDate": "22-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Dec-2021",
                "endDate": "10-May-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "09-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Committee Meetings",
                "status": "Positive Opinion",
                "milestoneDate": "20-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, in the pre-NDA meeting and the subsequent Meeting Memorandum, the FDA indicated that they would accept the NDA filing if submitted, and provided additional guidance regarding the submission. No other substantive issues were raised by the FDA [<ulink linkType=\"Reference\" linkID=\"2257044\">2257044</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In November 2019, the company planned to file a NDA  for the Dovitinib DPR in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2216390\">2216390</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2020, due to a reported delay in the manufacture of registration batch, the company expected to file the NDA in 2021 [<ulink linkType=\"Reference\" linkID=\"2345921\">2345921</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "02-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, the NDA was submitted to the US FDA for dovitinib DRP as companion diagnostic to dovitinib for renal cell carcinoma [<ulink linkType=\"Reference\" linkID=\"2430386\">2430386</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In September 2021, an NDA filing with the US FDA for the approval of dovitinib for the treatment of RCC was expected in the fourth quarter of 2021 [  <ulink linkID=\"2529753\" linkType=\"Reference\">  2529753  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "22-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a new drug application (NDA) was submitted to US FDA for seeking marketing approval for dovitinib for the third-line treatment of renal cell carcinoma patients [  <ulink linkID=\"2588304\" linkType=\"Reference\">  2588304  </ulink> ]. </para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Rejected",
                "milestoneDate": "18-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, US FDA provided the refusal to file (RTF) letters for the NDA of dovitinib, and it’s accompanying PMA application. At that time, A Type-C meeting was requested to discuss potential clinical paths to support the approval of dovitinib [  <ulink linkID=\"2632713\" linkType=\"Reference\">  2632713 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In May 2022, a type C meeting to discuss potential paths to approval for dovitinib was scheduled to held in second quarter of 2022 [ <ulink linkID=\"2670710\" linkType=\"Reference\">  2670710 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DK, NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2011",
            "endDate": "",
            "statusDate": "15-Jan-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2011",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DK",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Oct-2022",
            "endDate": "17-Feb-2031",
            "statusDate": "07-Oct-2022",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "13%",
            "timeToRegistration": "7.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-Oct-2022",
                "endDate": "16-Dec-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "16-Dec-2024",
                "endDate": "21-May-2027",
                "successPercentage": "37%",
                "predictedDateL50": "02-Apr-2024",
                "predictedDateU50": "01-May-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-May-2027",
                "endDate": "25-Jan-2030",
                "successPercentage": "50%",
                "predictedDateL50": "11-Mar-2026",
                "predictedDateU50": "26-Oct-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2030",
                "endDate": "07-Jan-2031",
                "successPercentage": "91%",
                "predictedDateL50": "07-Dec-2028",
                "predictedDateU50": "03-Jul-2030",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jan-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Sep-2030",
                "predictedDateU50": "17-Feb-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In March 2023, data from a phase Ib trial (NCT05571969) for advanced solid tumors, including ovarian cancer were expected in the first half of 2024 [ <ulink linkID=\"2864488\" linkType=\"Reference\">  2864488 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2022, a phase I trial (NCT05571969) was expected to complete in December 2024 [ <ulink linkID=\"2757036\" linkType=\"Reference\">  2757036 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1143038",
              "name": "OV-SPV2 ApS"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Mar-2023",
            "endDate": "12-May-2031",
            "statusDate": "20-Mar-2023",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Mar-2023",
                "endDate": "24-Jan-2025",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "24-Jan-2025",
                "endDate": "07-Aug-2027",
                "successPercentage": "28%",
                "predictedDateL50": "19-Apr-2024",
                "predictedDateU50": "01-Jun-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Aug-2027",
                "endDate": "07-Apr-2030",
                "successPercentage": "52%",
                "predictedDateL50": "11-May-2026",
                "predictedDateU50": "01-Feb-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Apr-2030",
                "endDate": "02-Apr-2031",
                "successPercentage": "93%",
                "predictedDateL50": "17-Feb-2029",
                "predictedDateU50": "08-Sep-2030",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Apr-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Dec-2030",
                "predictedDateU50": "12-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In March 2023, data from a phase Ib trial (NCT05571969) for advanced solid tumors, including ovarian cancer were expected in the first half of 2024 [ <ulink linkID=\"2864488\" linkType=\"Reference\">  2864488 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "53551",
        "displayName": "entolimod",
        "drugPrograms": [
          {
            "company": {
              "id": "1015134",
              "name": "Statera Biopharma Inc"
            },
            "indication": {
              "id": "367",
              "name": "Radiation sickness"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Orphan Drug, Animal Rule, Emergency Use Authorization",
            "startDate": "15-Oct-2008",
            "endDate": "",
            "statusDate": "15-Jun-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "15-Oct-2008",
                "endDate": "22-Dec-2010",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "22-Dec-2010",
                "endDate": "15-Jun-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jun-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015134",
              "name": "Statera Biopharma Inc"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2012",
            "endDate": "",
            "statusDate": "31-Jan-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Jan-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "55559",
        "displayName": "fluciclovine (18F)",
        "drugPrograms": [
          {
            "company": {
              "id": "1102488",
              "name": "Blue Earth Diagnostics Ltd"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Apr-2015",
            "endDate": "",
            "statusDate": "05-Jan-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Apr-2015",
                "endDate": "05-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "05-Jan-2019",
                "endDate": "24-Mar-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Mar-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1102488",
              "name": "Blue Earth Diagnostics Ltd"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Dec-2018",
            "endDate": "",
            "statusDate": "31-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1102488",
              "name": "Blue Earth Diagnostics Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Sep-2019",
            "endDate": "",
            "statusDate": "23-Sep-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "23-Sep-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1102488",
              "name": "Blue Earth Diagnostics Ltd"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Sep-2019",
            "endDate": "",
            "statusDate": "23-Sep-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "23-Sep-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1102488",
              "name": "Blue Earth Diagnostics Ltd"
            },
            "indication": {
              "id": "3471",
              "name": "Metastatic brain cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Jan-2023",
            "endDate": "16-Sep-2028",
            "statusDate": "10-Jan-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "64%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Jan-2023",
                "endDate": "30-Jun-2025",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2025",
                "endDate": "25-Nov-2027",
                "successPercentage": "78%",
                "predictedDateL50": "16-Sep-2024",
                "predictedDateU50": "19-Nov-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2027",
                "endDate": "09-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "09-Nov-2026",
                "predictedDateU50": "14-Apr-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-May-2028",
                "predictedDateU50": "16-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, a phase II trial (NCT05554302) was expected to be completed in June 2025 in the US for the diagnosis of resected brain metastasis [ <ulink linkID=\"2741936\" linkType=\"Reference\"> 2741936 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20573",
              "name": "Emory University"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Jul-2021",
            "endDate": "18-Jul-2029",
            "statusDate": "16-Jul-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "51%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "16-Jul-2021",
                "endDate": "31-Dec-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Dec-2024",
                "endDate": "12-Jun-2026",
                "successPercentage": "76%",
                "predictedDateL50": "11-Jul-2024",
                "predictedDateU50": "16-May-2025",
                "phaseDuration": "1.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Jun-2026",
                "endDate": "07-Sep-2028",
                "successPercentage": "78%",
                "predictedDateL50": "23-Sep-2025",
                "predictedDateU50": "01-Oct-2026",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Sep-2028",
                "endDate": "18-Jun-2029",
                "successPercentage": "95%",
                "predictedDateL50": "15-Sep-2027",
                "predictedDateU50": "26-Jan-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Mar-2029",
                "predictedDateU50": "18-Jul-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, a phase I trial (NCT04750473) was expected to complete in December 2024 [2411950].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20573",
              "name": "Emory University"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2017",
            "endDate": "",
            "statusDate": "01-Mar-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Mar-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "26383",
              "name": "Nihon Medi-Physics Co Ltd"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Jan-2011",
            "endDate": "",
            "statusDate": "01-Sep-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Jan-2011",
                "endDate": "01-Sep-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Sep-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "56308",
        "displayName": "CBT-1",
        "drugPrograms": [
          {
            "company": {
              "id": "15325",
              "name": "CBA Pharma Inc"
            },
            "indication": {
              "id": "651",
              "name": "Cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Dec-2016",
            "endDate": "",
            "statusDate": "27-Dec-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "27-Dec-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "56712",
        "displayName": "padeliporfin potassium",
        "drugPrograms": [
          {
            "company": {
              "id": "1040302",
              "name": "ImPact Biotech Ltd"
            },
            "indication": {
              "id": "276",
              "name": "Prostate tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2009",
            "endDate": "",
            "statusDate": "05-Apr-2023",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jul-2009",
                "endDate": "31-May-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-May-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1040302",
              "name": "ImPact Biotech Ltd"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Apr-2017",
            "endDate": "27-Dec-2029",
            "statusDate": "05-Apr-2023",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Apr-2017",
                "endDate": "09-Jun-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "09-Jun-2024",
                "endDate": "26-Aug-2026",
                "successPercentage": "37%",
                "predictedDateL50": "01-Jan-2024",
                "predictedDateU50": "25-Sep-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-Aug-2026",
                "endDate": "07-Jan-2029",
                "successPercentage": "54%",
                "predictedDateL50": "14-Jul-2025",
                "predictedDateU50": "26-Jan-2027",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Jan-2029",
                "endDate": "11-Nov-2029",
                "successPercentage": "90%",
                "predictedDateL50": "30-Dec-2027",
                "predictedDateU50": "27-May-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Nov-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Aug-2029",
                "predictedDateU50": "27-Dec-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1040302",
              "name": "ImPact Biotech Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Mar-2021",
            "endDate": "04-Feb-2030",
            "statusDate": "05-Apr-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "22-Mar-2021",
                "endDate": "25-Jan-2029",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2029",
                "endDate": "28-Dec-2029",
                "successPercentage": "91%",
                "predictedDateL50": "13-Sep-2028",
                "predictedDateU50": "01-May-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Dec-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Sep-2029",
                "predictedDateU50": "04-Feb-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "25-Jan-2029",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III study (NCT04620239; ENLIGHTED) of padeliporfin VTP for the treatment of upper tract urothelial carcinoma was expected to complete in January 2029 [ <ulink linkID=\"2358528\" linkType=\"Reference\"> 2358528 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1040302",
              "name": "ImPact Biotech Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jun-2018",
            "endDate": "13-Mar-2030",
            "statusDate": "05-Apr-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Jun-2018",
                "endDate": "22-Mar-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Mar-2021",
                "endDate": "25-Jan-2029",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jan-2029",
                "endDate": "25-Jan-2030",
                "successPercentage": "91%",
                "predictedDateL50": "13-Sep-2028",
                "predictedDateU50": "01-May-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Sep-2029",
                "predictedDateU50": "13-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "25-Jan-2029",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III study (NCT04620239; ENLIGHTED) of padeliporfin VTP for the treatment of upper tract urothelial carcinoma was expected to complete in January 2029 [ <ulink linkID=\"2358528\" linkType=\"Reference\"> 2358528 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "61456",
        "displayName": "avasopasem manganese",
        "drugPrograms": [
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "249",
              "name": "Pancreas tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Feb-2018",
            "endDate": "18-Mar-2027",
            "statusDate": "12-Feb-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Feb-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "36%",
                "predictedDateL50": "20-Apr-2023",
                "predictedDateU50": "14-Jul-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "09-Feb-2027",
                "successPercentage": "91%",
                "predictedDateL50": "08-Apr-2025",
                "predictedDateU50": "04-Sep-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Oct-2026",
                "predictedDateU50": "18-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, top-line data expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2227185\">2227185</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2020",
                "milestoneExtendedDate": "28-Oct-2020",
                "notes": "In September 2020, top-line data from a phase I/II trial (NCT03340974) in locally advanced pancreatic cancer was expecetd in October 2020 [<ulink linkType=\"Reference\" linkID=\"2316248\">2316248</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, interim data of intent-to-treat cohort (n = 19) enrolled in the first, single-center stage of the trial were reported [<ulink linkType=\"Reference\" linkID=\"2346785\">2346785</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "28-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, an updated results from phase I/II trial (NCT03340974) in patients with locally advanced pancreatic cancer were reported [<ulink linkType=\"Reference\" linkID=\"2443964\">2443964</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "30-Sep-2021",
                "notes": "In August 2021, final data from a pilot phase I/II study (NCT03340974) were expected in in the third quarter of 2021 [ <ulink linkID=\"2508478\" linkType=\"Reference\">  2508478 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021, final study data from a pilot phase I/II study (NCT03340974) were expected in second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2420122\">2420122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In February 2018, a phase I/II trial was expected to complete in June 2022 [<ulink linkType=\"Reference\" linkID=\"2074830\">2074830</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "810",
              "name": "Esophagitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Dec-2019",
            "endDate": "18-Mar-2027",
            "statusDate": "19-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Dec-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "04-Apr-2026",
                "successPercentage": "33%",
                "predictedDateL50": "20-May-2023",
                "predictedDateU50": "05-Jun-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2026",
                "endDate": "02-Feb-2027",
                "successPercentage": "93%",
                "predictedDateL50": "06-Apr-2025",
                "predictedDateU50": "20-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Oct-2026",
                "predictedDateU50": "18-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In January 2020, a phase II trial (NCT04225026) for radiation induced esophagitis was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2237486\">2237486</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In March 2021, top-line data from a single-group assignment trial (NCT04225026) was expected in first half of 2022 [<ulink linkType=\"Reference\" linkID=\"2420122\">2420122</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, positive topline results from phase II trial (NCT04225026) for esophagitis in the US demonstrating good tolerability were reported [  <ulink linkID=\"2661148\" linkType=\"Reference\">  2661148 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "2562",
              "name": "Adult respiratory distress syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Sep-2020",
            "endDate": "26-Feb-2027",
            "statusDate": "09-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Sep-2020",
                "endDate": "08-Apr-2024",
                "successPercentage": "66%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Apr-2024",
                "endDate": "15-Apr-2026",
                "successPercentage": "48%",
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "27-Jun-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Apr-2026",
                "endDate": "27-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "31-May-2025",
                "predictedDateU50": "20-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Oct-2026",
                "predictedDateU50": "26-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In September 2020, a phase II trial (NCT04555096) of GC-4419 in patients with critical illness due to COVID-19 was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2326310\">2326310</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "3209",
              "name": "Oral mucositis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Breakthrough Therapy, Priority Review",
            "startDate": "16-Jun-2010",
            "endDate": "02-May-2024",
            "statusDate": "12-Dec-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "16-Jun-2010",
                "endDate": "31-Aug-2013",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2013",
                "endDate": "03-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Oct-2018",
                "endDate": "12-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Dec-2022",
                "endDate": "02-Apr-2024",
                "successPercentage": "12%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Feb-2024",
                "predictedDateU50": "02-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "07-Jan-2016",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "28-Feb-2018",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, results from the phase IIb trial (NCT02508389) were presented at the 54th ASCO Annual Meeting in Chicago, IL. Median duration of SOM (primary outcome) was 19, 8 and 1.5 days in the placebo, 30 mg and 90 mg groups, respectively (p = 0.163 and p = 0.024 for 30 mg and 60 mg versus placebo, respectively). A 92% decrease in median duration of SOM was observed. Incidence of SOM (secondary endpoint) was 58, 40 (p = 0.026 versus placebo) and 37% (p = 0.010 versus placebo); incidence of grade 3/4 SOM was 65, 60 and 43% (p = 0.009 versus placebo) and that of grade 4 oral mucositis was 30, 21 and 16% (p = 0.045 versus placebo) with placebo, 30 mg and 90 mg, respectively. Safety profile was similar between groups without significant GC4419-specific toxicity or increased toxicity of intensity-modulated radiotherapy/cisplatin [<ulink linkType=\"Reference\" linkID=\"2039216\">2039216</ulink>], [<ulink linkType=\"Reference\" linkID=\"2083704\">2083704</ulink>], [<ulink linkType=\"Reference\" linkID=\"2083705\">2083705</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, results from the phase IIb trial (NCT02508389) were presented at the 54th ASCO Annual Meeting in Chicago, IL. Median duration of SOM (primary outcome) was 19, 8 and 1.5 days in the placebo, 30 mg and 90 mg groups, respectively (p = 0.163 and p = 0.024 for 30 mg and 60 mg versus placebo, respectively). A 92% decrease in median duration of SOM was observed. Incidence of SOM (secondary endpoint) was 58, 40 (p = 0.026 versus placebo) and 37% (p = 0.010 versus placebo); incidence of grade 3/4 SOM was 65, 60 and 43% (p = 0.009 versus placebo) and that of grade 4 oral mucositis was 30, 21 and 16% (p = 0.045 versus placebo) with placebo, 30 mg and 90 mg, respectively. Safety profile was similar between groups without significant GC4419-specific toxicity or increased toxicity of intensity-modulated radiotherapy/cisplatin [<ulink linkType=\"Reference\" linkID=\"2039216\">2039216</ulink>], [<ulink linkType=\"Reference\" linkID=\"2083704\">2083704</ulink>], [<ulink linkType=\"Reference\" linkID=\"2083705\">2083705</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "31-Oct-2018",
                "notes": "Later that month, the randomized, double-blind, placebo-controlled, multicenter, phase III trial NCT03689712; GTI-4419-301) to evaluate GC-4419 to reduce severe oral mucositis associated with chemoradiotherapy for locally advanced, non-metastatic head and neck cancer patients (expected n = 335) was planned in October 2018. The primary outcome was the cumulative incidence of severe oral mucositis. At that time, the trial was expected to complete in October 2024 [<ulink linkType=\"Reference\" linkID=\"2079092\">2079092</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "31-Dec-2018",
                "notes": "In September 2018, a pivotal phase III trial was expected to be initiated in the fourth quarter of 2018 [<ulink linkType=\"Reference\" linkID=\"2074474\">2074474</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "08-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, positive final data from two-year tumor outcomes follow up of patients in a phase II study (NCT02508389) were reported [<ulink linkType=\"Reference\" linkID=\"2202748\">2202748</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In October 2019, topline results from the phase III study (NCT03689712; ROMAN) were expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2202748\">2202748</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In August 2020, top-line data from a phase III trial (NCT03689712; ROMAN) were expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2307835\">2307835</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the results from the Phase III ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of SOM [ <ulink linkID=\"2551278\" linkType=\"Reference\">  2551278 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "14-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, corrected data were reported from the phase III ROMAN trial. Data demonstrated that avasopasem achieved statistical significance on the primary endpoint of reduction in the incidence of SOM [ <ulink linkID=\"2583529\" linkType=\"Reference\">  2583529 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "14-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, corrected data were reported from the phase III ROMAN trial [ <ulink linkID=\"2583529\" linkType=\"Reference\">  2583529 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In May 2022, the company planned to file NDA for the treatment of severe oral mucositis in patients with head and neck cancer by the end of 2022 [ <ulink linkID=\"2670039\" linkType=\"Reference\">  2670039 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "12-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, an NDA was submitted to the US FDA for the treatment of severe oral mucositis in patients with head and neck cancer [ <ulink linkID=\"2790693\" linkType=\"Reference\">  2790693 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2023, drug was expected to be launched in 2023 [ <ulink linkID=\"2916553\" linkType=\"Reference\"> 2916553 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "08-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, the US FDA granted priority review designation for radiotherapy-induced severe oral mucositis (SOM) [ <ulink linkID=\"2850142\" linkType=\"Reference\">  2850142 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "09-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, the NDA filing was accepted by the US FDA and the prescription drug user fee act (PDUFA) target date was August 9, 2023. The FDA revealed at the time that it had no plans to hold a meeting of the advisory group to discuss the application [ <ulink linkID=\"2823951\" linkType=\"Reference\"> 2823951 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "14-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the company received CRL for submitted NDA communicating that additional clinical trial would be required for resubmission [ <ulink linkID=\"3040516\" linkType=\"Reference\"> 3040516 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Negative Opinion",
                "milestoneDate": "28-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the minutes from the Type A meeting were announced. According to the US FDA the data from the GT-201 were insufficient for the NDA approval and suggested an additional Phase III trial [ <ulink linkID=\"3485288\" linkType=\"Reference\"> 3485288 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Planned",
                "milestoneDate": "28-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a Type A meeting with the US FDA was planned on September 28, 2023, to seek approval for the drug for the treatment of severe oral mucositis in patients with head and neck cancer [ <ulink linkID=\"3199765\" linkType=\"Reference\"> 3199765 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "3209",
              "name": "Oral mucositis"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Promising Innovative Medicine",
            "startDate": "01-Jun-2020",
            "endDate": "26-Feb-2027",
            "statusDate": "01-Jun-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "71%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "14-Feb-2026",
                "successPercentage": "79%",
                "predictedDateL50": "14-May-2023",
                "predictedDateU50": "04-May-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2026",
                "endDate": "17-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Feb-2025",
                "predictedDateU50": "26-Jun-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Oct-2026",
                "predictedDateU50": "26-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021, top-line data from a multicenter phase IIa study (EUSOM) in Europe was expected in second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2420122\">2420122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In August 2020, a phase II trial (NCT04529850) in severe oral mucositis associated with chemoradiotherapy for locally advanced, non-metastatic head and neck cancer was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2323389\">2323389</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "14-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, top-line data were reported from the phase IIa EUSOM trial of avasopasem in Europe [ <ulink linkID=\"2583529\" linkType=\"Reference\">  2583529 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, a phaseIIa EUSOM trial of avasopasem was completed in Europe [ <ulink linkID=\"2759195\" linkType=\"Reference\">  2759195 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1054887",
              "name": "Galera Therapeutics Inc"
            },
            "indication": {
              "id": "10406",
              "name": "Coronavirus disease 19 infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Sep-2020",
            "endDate": "28-Mar-2027",
            "statusDate": "09-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Sep-2020",
                "endDate": "05-Apr-2024",
                "successPercentage": "66%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Apr-2024",
                "endDate": "28-Apr-2026",
                "successPercentage": "36%",
                "predictedDateL50": "01-Jan-2024",
                "predictedDateU50": "11-Jun-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Apr-2026",
                "endDate": "23-Feb-2027",
                "successPercentage": "89%",
                "predictedDateL50": "05-Jun-2025",
                "predictedDateU50": "31-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Nov-2026",
                "predictedDateU50": "28-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In November 2020, top-line data from a phase II trial (NCT04555096) were expected in the first half of 2021 in patients with critical illness due to COVID-19 [2357666].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In September 2020, a phase II trial (NCT04555096) of GC-4419 in patients with critical illness due to COVID-19 was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2326310\">2326310</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "62015",
        "displayName": "rituximab + hyaluronidase (Non-Hodgkin's lymphoma/diffuse large B-cell lymphoma/chronic lymphocytic leukemia, Enhanze), Roche/Halozyme",
        "drugPrograms": [
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Nov-2016",
            "endDate": "",
            "statusDate": "22-Nov-2016",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-6.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "22-Nov-2016",
                "endDate": "22-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jun-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "63262",
        "displayName": "sodium pyruvate (inhaled, COPD/pulmonary fibrosis/interstitial lung disease/cystic fibrosis/ashtma/viral infections/COVID-19), EmphyCorp/PharmaMax",
        "drugPrograms": [
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "31",
              "name": "Asthma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2006",
            "endDate": "",
            "statusDate": "31-Jan-2006",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2006",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "88",
              "name": "Cystic fibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Mar-2006",
            "endDate": "",
            "statusDate": "28-Feb-2006",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2006",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "191",
              "name": "Influenza virus infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Apr-2021",
            "endDate": "16-Mar-2025",
            "statusDate": "12-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "12-Apr-2021",
                "endDate": "18-Mar-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Mar-2024",
                "endDate": "05-Feb-2025",
                "successPercentage": "88%",
                "predictedDateL50": "30-Dec-2023",
                "predictedDateU50": "24-May-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Oct-2024",
                "predictedDateU50": "16-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "708",
              "name": "Pulmonary fibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Aug-2019",
            "endDate": "",
            "statusDate": "15-Aug-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Aug-2019",
                "endDate": "15-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Aug-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2004",
            "endDate": "",
            "statusDate": "15-Aug-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2004",
                "endDate": "15-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "14.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Aug-2019",
                "endDate": "15-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Aug-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "2466",
              "name": "Interstitial lung disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "15-Aug-2019",
            "endDate": "",
            "statusDate": "15-Aug-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Aug-2019",
                "endDate": "15-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Aug-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "3771",
              "name": "Idiopathic pulmonary fibrosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Aug-2023",
            "endDate": "20-Aug-2026",
            "statusDate": "15-Aug-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Aug-2023",
                "endDate": "28-Aug-2025",
                "successPercentage": "56%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Aug-2025",
                "endDate": "09-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "08-Oct-2024",
                "predictedDateU50": "01-Jan-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Mar-2026",
                "predictedDateU50": "20-Aug-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, a phase III trial (NCT06037408) in coughing patients for the treatment of IPF was expected to complete in August 2024 [ <ulink linkID=\"3197801\" linkType=\"Reference\"> 3197801 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1007974",
              "name": "EmphyCorp Inc"
            },
            "indication": {
              "id": "10406",
              "name": "Coronavirus disease 19 infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Apr-2021",
            "endDate": "07-Dec-2024",
            "statusDate": "12-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "71%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "12-Apr-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "29-Oct-2024",
                "successPercentage": "88%",
                "predictedDateL50": "22-Sep-2023",
                "predictedDateU50": "15-Feb-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Jul-2024",
                "predictedDateU50": "07-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "05-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, a phase III trial for COVID-19, long COVID-19 (Long Haulers), and pulmonary fibrosis was completed, results were reported [ <ulink linkID=\"2541913\" linkType=\"Reference\">  2541913 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "05-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, a phase III trial for COVID-19, long COVID-19 (Long Haulers), and pulmonary fibrosis was completed [ <ulink linkID=\"2541913\" linkType=\"Reference\">  2541913 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In April 2021, a phase II/III trial (NCT04824365) in COVID-19 and influenza infections was expected to complete in June 2022 [ <ulink linkID=\"2543138\" linkType=\"Reference\">  2543138 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "71145",
        "displayName": "eflornithine + sulindac",
        "drugPrograms": [
          {
            "company": {
              "id": "1052205",
              "name": "Cancer Prevention Pharmaceuticals Inc"
            },
            "indication": {
              "id": "767",
              "name": "Colon tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2000",
            "endDate": "",
            "statusDate": "30-Jun-2005",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2000",
                "endDate": "30-Jun-2005",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2005",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052205",
              "name": "Cancer Prevention Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1277",
              "name": "Familial adenomatous polyposis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Oct-2013",
            "endDate": "",
            "statusDate": "29-Jun-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Oct-2013",
                "endDate": "29-Jun-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jun-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052205",
              "name": "Cancer Prevention Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1277",
              "name": "Familial adenomatous polyposis"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Oct-2013",
            "endDate": "",
            "statusDate": "31-Oct-2013",
            "phaseHighestStatus": "Failed",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "30-Sep-2017",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Oct-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052205",
              "name": "Cancer Prevention Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3704",
              "name": "Adenoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2000",
            "endDate": "",
            "statusDate": "30-Jun-2005",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2000",
                "endDate": "30-Jun-2005",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2005",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "72209",
        "displayName": "melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma), Delcath",
        "drugPrograms": [
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "202",
              "name": "Liver tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2004",
            "endDate": "",
            "statusDate": "15-Aug-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2004",
                "endDate": "28-Feb-2006",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Feb-2006",
                "endDate": "15-Aug-2012",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Aug-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2014",
            "endDate": "",
            "statusDate": "13-Apr-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Jun-2014",
            "endDate": "11-Dec-2024",
            "statusDate": "07-May-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2014",
                "endDate": "07-May-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-May-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "02-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "26-Jul-2023",
                "predictedDateU50": "25-Apr-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jul-2024",
                "predictedDateU50": "11-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "14-Jul-2015",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2018",
                "milestoneExtendedDate": "",
                "notes": "<para>Source Date: 04/10/2018; Phase: C3 In September 2018, positive results were published from the phase II/III trial NCT03086993 Data demonstrated the drug to be safe and well tolerated. The first PHP treatment showed complete response in one patient (7%), partial response in 2 (13%) and stable disease in 8 patients (53%). The median overall survival was 26.9 months from initial diagnosis and 7.6 months from first PHP treatment. The median PFS and hPFS were 122 and 131 days, respectively [<ulink linkType=\"Reference\" linkID=\"2079539\">2079539</ulink>], [<ulink linkType=\"Reference\" linkID=\"2079903\">2079903</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a single-center study positive data were reported [ <ulink linkID=\"2785012\" linkType=\"Reference\">  2785012 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Jun-2014",
            "endDate": "",
            "statusDate": "07-May-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2014",
                "endDate": "07-May-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-May-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2014",
            "endDate": "",
            "statusDate": "07-May-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2014",
                "endDate": "07-May-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-May-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "3788",
              "name": "Uveal melanoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2019",
            "endDate": "08-Jul-2027",
            "statusDate": "04-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Dec-2019",
                "endDate": "09-Jan-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Jan-2024",
                "endDate": "31-May-2026",
                "successPercentage": "70%",
                "predictedDateL50": "03-Jul-2023",
                "predictedDateU50": "22-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-May-2026",
                "endDate": "27-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-May-2025",
                "predictedDateU50": "18-Oct-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jan-2027",
                "predictedDateU50": "08-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, additional data from the phase Ib/randomized phase II trial (NCT04283890) in patients with unresectable hepatic and extrahepatic metastases of uveal melanoma were reported [ <ulink linkID=\"2811399\" linkType=\"Reference\">  2811399 </ulink>], [ <ulink linkID=\"2808809\" linkType=\"Reference\">  2808809 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, the phase Ib/randomized phase II trial (NCT04283890) in patients with unresectable hepatic and extrahepatic metastases of uveal melanoma was expected to complete in December 2024 [ <ulink linkID=\"2475940\" linkType=\"Reference\">  2475940 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "3789",
              "name": "Ocular melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "28-Feb-2006",
            "endDate": "",
            "statusDate": "14-Feb-2023",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Feb-2006",
                "endDate": "14-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "17.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2023",
                "endDate": "14-Aug-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Aug-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1011058",
              "name": "Delcath Systems Inc"
            },
            "indication": {
              "id": "3789",
              "name": "Ocular melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Feb-2014",
            "endDate": "",
            "statusDate": "06-Jul-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Feb-2014",
                "endDate": "06-Jul-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "76613",
        "displayName": "trastuzumab duocarmazine",
        "drugPrograms": [
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (BE, GB, NL)"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "27-Oct-2014",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "BE",
              " GB",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (BE, GB, NL)"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "27-Oct-2014",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "BE",
              " GB",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (BE, GB, PL)"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "22-Jun-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "BE",
              " GB",
              " PL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "28-May-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "28-May-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe(BE, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Oct-2014",
            "endDate": "22-Jan-2025",
            "statusDate": "22-Jun-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Oct-2014",
                "endDate": "15-Dec-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Dec-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "07-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "19-Mar-2023",
                "predictedDateU50": "30-Mar-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Aug-2024",
                "predictedDateU50": "22-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Withdrawn",
                "milestoneDate": "12-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, marketing authorization application of drug for the treatment of HER2-positive breast cancer was withdrawn [ <ulink linkID=\"3430894\" linkType=\"Reference\"> 3430894 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "BE",
              " GB",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2017",
            "endDate": "14-Jan-2025",
            "statusDate": "30-Nov-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "05-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "12-Feb-2023",
                "predictedDateU50": "20-May-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Aug-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "12-Jul-2022",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe (BE, GB)"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "22-Jun-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "BE",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1312169",
              "name": "Byondis BV"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (BE, GB)"
            },
            "principalCompany": {
              "id": "29996",
              "name": "Syntarga BV"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "22-Jun-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "BE",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "78939",
        "displayName": "bevacizumab biosimilar, Celltrion",
        "drugPrograms": [
          {
            "company": {
              "id": "1015645",
              "name": "Celltrion"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2021",
            "endDate": "28-Sep-2022",
            "statusDate": "30-Sep-2021",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2021",
                "endDate": "28-Sep-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Sep-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "30-Sep-2022",
                "notes": "In August 2022, approval from the US FDA was expected in third quarter of 2022 [  <ulink linkID=\"2721227\" linkType=\"Reference\">  2721227 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "79064",
        "displayName": "bevacizumab biosimilar, Mylan/Biocon",
        "drugPrograms": [
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "651",
              "name": "Cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "07-May-2015",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Jul-2016",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18439",
              "name": "Mylan NV"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2020",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "09-Mar-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "651",
              "name": "Cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-May-2015",
            "endDate": "",
            "statusDate": "07-May-2015",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "07-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Jul-2016",
            "endDate": "",
            "statusDate": "11-Jul-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2020",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Mar-2020",
                "endDate": "09-Mar-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Mar-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2020",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "09-Mar-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2020",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "09-Mar-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "28769",
              "name": "Biocon Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2020",
            "endDate": "",
            "statusDate": "09-Mar-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "09-Mar-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "81415",
        "displayName": "lifileucel",
        "drugPrograms": [
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Fast Track, Breakthrough Therapy",
            "startDate": "30-Mar-2015",
            "endDate": "12-Jul-2032",
            "statusDate": "05-Apr-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "8.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Mar-2015",
                "endDate": "05-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "05-Apr-2017",
                "endDate": "16-Dec-2030",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "13.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2030",
                "endDate": "16-Jun-2031",
                "successPercentage": "68%",
                "predictedDateL50": "16-Nov-2029",
                "predictedDateU50": "21-Jun-2031",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Jun-2031",
                "endDate": "01-Jun-2032",
                "successPercentage": "86%",
                "predictedDateL50": "17-Dec-2030",
                "predictedDateU50": "01-Nov-2031",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jun-2032",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Feb-2032",
                "predictedDateU50": "12-Jul-2032",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2018",
                "milestoneExtendedDate": "",
                "notes": "In January 2018, preliminary results from the phase II trial (NCT03108495) in patients with recurrent and or metastatic cervical carcinoma were reported from two evaluable patients showing that one had PR and  another had  stable disease following treatment with LN-145 [<ulink linkType=\"Reference\" linkID=\"1999811\">1999811</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "30-Apr-2018",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, preliminary data from the phase II trial (NCT03108495) were reported. Stage one was completed and enrollment in the study continued. Preliminary data for 15 patients yielded an ORR of 27% with an early look at the DOR ranging from 2.4 to 2.5+ months [<ulink linkType=\"Reference\" linkID=\"2081885\">2081885</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "28-Feb-2019",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, LN-145 received Fast Track designation from the FDA for the cervical cancer [<ulink linkType=\"Reference\" linkID=\"2149182\">2149182</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "22-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, LN-145 received Breakthrough Therapy designation from the FDA for the recurrent, metastatic, or persistent cervical cancer [<ulink linkType=\"Reference\" linkID=\"2154650\">2154650</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2020, a BLA for cervical cancer patients with recurrent, persistent, or metastatic disease who have progressed during or after chemotherapy was expected by the end of 2020 [<ulink linkType=\"Reference\" linkID=\"2251454\">2251454</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2030",
                "milestoneExtendedDate": "31-Dec-2030",
                "notes": "In September 2023, a phase II trial (NCT03108495) in cervical carcinoma was expected to complete in December 2030 [ <ulink linkID=\"1917973\" linkType=\"Reference\"> 1917973 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Oct-2018",
            "endDate": "09-Dec-2034",
            "statusDate": "11-Oct-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "10.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Oct-2018",
                "endDate": "16-Dec-2030",
                "successPercentage": "44%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2030",
                "endDate": "08-Jul-2033",
                "successPercentage": "10%",
                "predictedDateL50": "22-Dec-2029",
                "predictedDateU50": "21-Jul-2031",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jul-2033",
                "endDate": "22-Sep-2034",
                "successPercentage": "75%",
                "predictedDateL50": "29-May-2032",
                "predictedDateU50": "21-Nov-2033",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Sep-2034",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Apr-2034",
                "predictedDateU50": "09-Dec-2034",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2030",
                "milestoneExtendedDate": "31-Dec-2030",
                "notes": "In September 2023, a phase II trial (NCT03108495) in cervical carcinoma was expected to complete in December 2030 [ <ulink linkID=\"1917973\" linkType=\"Reference\"> 1917973 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2018",
            "endDate": "12-Sep-2028",
            "statusDate": "27-Apr-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2018",
                "endDate": "02-Jan-2025",
                "successPercentage": "19%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Jan-2025",
                "endDate": "26-Jul-2027",
                "successPercentage": "16%",
                "predictedDateL50": "20-Mar-2024",
                "predictedDateU50": "04-Sep-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jul-2027",
                "endDate": "25-Jul-2028",
                "successPercentage": "79%",
                "predictedDateL50": "16-Jun-2026",
                "predictedDateU50": "09-Dec-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Mar-2028",
                "predictedDateU50": "12-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2018",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "1507",
              "name": "Pancreatic ductal adenocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Aug-2018",
            "endDate": "11-Feb-2029",
            "statusDate": "17-Aug-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Aug-2018",
                "endDate": "22-Apr-2025",
                "successPercentage": "14%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Apr-2025",
                "endDate": "12-Jan-2028",
                "successPercentage": "17%",
                "predictedDateL50": "17-Mar-2024",
                "predictedDateU50": "21-Feb-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jan-2028",
                "endDate": "01-Jan-2029",
                "successPercentage": "90%",
                "predictedDateL50": "17-Nov-2026",
                "predictedDateU50": "18-Jun-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jan-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Sep-2028",
                "predictedDateU50": "11-Feb-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2018",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "05-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data from a phase II trial (NCT03610490) in patients with metastatic colorectal, pancreatic and ovarian cancers were presented. Grade 3 toxicities which were attributed to therapy included anemia (44%), febrile neutropenia (13%), hypophosphatemia (13%), hypotension (6%), neutropenia (6%) and thrombocytopenia (6%), and grade 4 were neutropenia (25%) and thrombocytopenia (75%). There were no responders; in colorectal (n = 8), pancreatic ductal adenocarcinoma (n = 5) and ovarian cancer (n = 3) patients, stable disease was achieved by three, one and two patients and progressive disease was seen in five, four and one patients, respectively [ <ulink linkID=\"2692218\" linkType=\"Reference\">  2692218 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "1772",
              "name": "Osteosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2018",
            "endDate": "18-May-2029",
            "statusDate": "27-Apr-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2018",
                "endDate": "21-Jul-2025",
                "successPercentage": "18%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jul-2025",
                "endDate": "19-Apr-2028",
                "successPercentage": "17%",
                "predictedDateL50": "21-May-2024",
                "predictedDateU50": "21-May-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Apr-2028",
                "endDate": "08-Apr-2029",
                "successPercentage": "90%",
                "predictedDateL50": "22-Feb-2027",
                "predictedDateU50": "02-Oct-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Apr-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Dec-2028",
                "predictedDateU50": "18-May-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Aug-2018",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2018, Iovance collaborating MD Anderson Cancer Center sponsored open-label, single-group assignment, phase II study NCT03610490>; 2017-0671; NCI-2018-01509) to evaluate the safety and efficcay of autologous tumor infiltrating lymphocyte cell therapy in treating participants (expected n = 60) with ovarian cancer, osteosarcoma, or pancreatic ductal adenocarcinoma was planned to be initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2064319\">2064319</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3256",
              "name": "Stage III melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Paediatric Investigation Plan",
            "startDate": "30-Sep-2015",
            "endDate": "03-Dec-2028",
            "statusDate": "24-Aug-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2015",
                "endDate": "15-Jan-2025",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Jan-2025",
                "endDate": "25-Aug-2027",
                "successPercentage": "19%",
                "predictedDateL50": "22-Feb-2024",
                "predictedDateU50": "10-Dec-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2027",
                "endDate": "04-Oct-2028",
                "successPercentage": "70%",
                "predictedDateL50": "13-Jul-2026",
                "predictedDateU50": "16-Jan-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Oct-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-May-2028",
                "predictedDateU50": "03-Dec-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Paediatric Investigation Plan",
                "status": "Positive Opinion",
                "milestoneDate": "23-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, the EMA's PDCO adopted positive opinion on agreeing changes for the lifileucel for the treatment of all conditions included in the category of malignant neoplasms [ <ulink linkID=\"2622837\" linkType=\"Reference\"> 2622837 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Jan-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase II trial (NCT02360579) in metastatic melanoma was expected to complete in January 2025 [ <ulink linkID=\"1694830\" linkType=\"Reference\"> 1694830 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3256",
              "name": "Stage III melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Regenerative Medicine Advanced Therapy, Fast Track, Priority Review",
            "startDate": "25-Aug-2022",
            "endDate": "21-Mar-2024",
            "statusDate": "25-Aug-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "83%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2022",
                "endDate": "10-Feb-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Dec-2023",
                "predictedDateU50": "21-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, data from phase I/II trial (NCT05176470) in stage IIIB-D was expected in second half of 2022 [  <ulink linkID=\"2714601\" linkType=\"Reference\">  2714601 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, approval of the drug for the treatment of advanced melanoma was expected in that same year [ <ulink linkID=\"2839249\" linkType=\"Reference\"> 2839249 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, approval of the drug for the treatment of advanced melanoma was expected in that same year [ <ulink linkID=\"2839249\" linkType=\"Reference\"> 2839249 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "24-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, submission of BLA for advanced (unresectable or metastatic) melanoma was completed [ <ulink linkID=\"2871221\" linkType=\"Reference\"> 2871221 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "26-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the US FDA granted Priority Review for the treatment of advanced melanoma [ <ulink linkID=\"2956649\" linkType=\"Reference\"> 2956649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Other Outcome",
                "milestoneDate": "14-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a meeting with the US FDA was completed. At that time, the US FDA extended the PDUFA target action date to February 24, 2024, due to insufficient resources to review the BLA [ <ulink linkID=\"3195223\" linkType=\"Reference\"> 3195223 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "25-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the US FDA accepted the BLA, granted Priority Review and set a PDUFA target action date of November 25, 2023 [ <ulink linkID=\"2956649\" linkType=\"Reference\"> 2956649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "24-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA extended the PDUFA target action date to February 24, 2024, due to insufficient resources to review the BLA [ <ulink linkID=\"3195223\" linkType=\"Reference\"> 3195223 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Paediatric Investigation Plan",
            "startDate": "30-Sep-2015",
            "endDate": "20-Nov-2028",
            "statusDate": "24-Aug-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2015",
                "endDate": "15-Jan-2025",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Jan-2025",
                "endDate": "08-Aug-2027",
                "successPercentage": "16%",
                "predictedDateL50": "31-May-2024",
                "predictedDateU50": "14-Nov-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2027",
                "endDate": "19-Sep-2028",
                "successPercentage": "62%",
                "predictedDateL50": "29-Jun-2026",
                "predictedDateU50": "22-Dec-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-May-2028",
                "predictedDateU50": "20-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, data from the ongoing phase II trial (NCT02360579) from 46 subjects were reported. An objective response rate (ORR) of 37% was observed in the cohort, with duration of response (DOR) ranging from 1.3+ to 14+ months depending on time of enrollment. The ORR included one complete response and 16 partial responses, six of which are unconfirmed and pending patient's upcoming second assessments [<ulink linkType=\"Reference\" linkID=\"2081885\">2081885</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, data from the subgroup analysis of cohort 2 in a phase II trial (NCT02360579) of advanced metastatic melanoma patients were reported [<ulink linkType=\"Reference\" linkID=\"2220596\">2220596</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2020, top-line data from the phase II trial (NCT02360579) in patients with metastatic melanoma were expected in 2020 [<ulink linkType=\"Reference\" linkID=\"2248780\">2248780</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Paediatric Investigation Plan",
                "status": "Positive Opinion",
                "milestoneDate": "23-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, the EMA's PDCO adopted positive opinion on agreeing changes for the lifileucel for the treatment of all conditions included in the category of malignant neoplasms [ <ulink linkID=\"2622837\" linkType=\"Reference\">  2622837 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, further data from a phase II trial (NCT03645928) in patients with unresectable or metastatic melanoma and metastatic HNSCC were presented. In the full analysis set across cohorts 1A (unresectable or metastatic melanoma; n = 8) and 2A (advanced, recurrent, or metastatic HNSCC; n = 14), ORR was 87.5 and 42.9%; CR rate was 37.5 and 7.1%; unconfirmed CR rate was 0.0 and 7.1%; PR rate was 37.5 and 28.6%; unconfirmed PR rate was 12.5 and 0.0%; SD rate was 12.5 and 50.0%; DCR was 100.0 and 92.9%, respectively. In the efficacy evaluable set across cohorts 1A (n = 8) and 2A (n = 13), ORR was 87.5 and 46.2%; seven and eight patients respectively had &gt; 30% change from baseline in target lesion sum of diameters [ <ulink linkID=\"2567222\" linkType=\"Reference\">  2567222 </ulink>],</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Jan-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase II trial (NCT02360579) in metastatic melanoma was expected to complete in January 2025 [ <ulink linkID=\"1694830\" linkType=\"Reference\"> 1694830 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Fast Track, Regenerative Medicine Advanced Therapy, Priority Review",
            "startDate": "30-Sep-2013",
            "endDate": "22-Mar-2024",
            "statusDate": "25-Aug-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2013",
                "endDate": "25-Aug-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2022",
                "endDate": "10-Feb-2024",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Dec-2023",
                "predictedDateU50": "22-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "09-Jun-2015",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "31-Aug-2017",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Regenerative Medicine Advanced Therapy",
                "status": "Granted",
                "milestoneDate": "11-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, lifileucel was granted a Regenerative Medicine Advanced Therapy (RMAT) designation in advanced melanoma [<ulink linkType=\"Reference\" linkID=\"2081885\">2081885</ulink>].\n</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, data from the ongoing phase II trial (NCT02360579) from 46 subjects were reported. An objective response rate (ORR) of 37% was observed in the cohort, with duration of response (DOR) ranging from 1.3+ to 14+ months depending on time of enrollment. The ORR included one complete response and 16 partial responses, six of which are unconfirmed and pending patient's upcoming second assessments [<ulink linkType=\"Reference\" linkID=\"2081885\">2081885</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, further Cohort-2 data from the phase II trial (NCT02360579) of advanced metastatic melanoma patients (n = 47) were presented at the 33rd SITC Annual Meeting in Washington DC. Tumor burden reduction was observed in 72% of patients. Median follow-up was 6 months. Objective response rate was 38% with one complete response, 17 partial responses, 18 stable diseases and 7 progression diseases. Disease control rate was 77%. Of 17, 16 had no response to prior anti-PD-1. Median duration of response was 6.4 months (DOR ranged from 1.3 + to 14+ months). Thrombocytopenia, chills, neutropenia, febrile neutropenia, anemia, pyrexia, hypophosphatemia, leucopenia, fatigue, hypotension, lymphopenia and tachycardia were the treatment-emergent adverse events. No grade 5 TEAEs were reported [<ulink linkType=\"Reference\" linkID=\"2092991\">2092991</ulink>], [<ulink linkType=\"Reference\" linkID=\"2091305\">2091305</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, data from the subgroup analysis of cohort 2 in a phase II trial (NCT02360579) of advanced metastatic melanoma patients were reported [<ulink linkType=\"Reference\" linkID=\"2220596\">2220596</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In May 2019, regulatory submission was planned for late 2020 for advanced melanoma [<ulink linkType=\"Reference\" linkID=\"2149182\">2149182</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2020, top-line data from the phase II trial (NCT02360579) in patients with metastatic melanoma were expected in 2020 [<ulink linkType=\"Reference\" linkID=\"2248780\">2248780</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2020, Iovance reported that it and the FDA had not been able to agree in the type B meeting on the required potency assays for defining the therapy, and as a result the BLA filing was expected to be delayed from 2020 to 2021 [<ulink linkType=\"Reference\" linkID=\"2338496\">2338496</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "04-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "By November 2021, the FDA had granted Fast Track designation for lifileucel in combination with pembrolizumab for the treatment of metastatic melanoma based on the unmet medical need and potential advantages for this combination over available care [ <ulink linkID=\"2560971\" linkType=\"Reference\">  2560971 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, further data from a phase II trial (NCT03645928) in patients with unresectable or metastatic melanoma and metastatic HNSCC were presented. In the full analysis set across cohorts 1A (unresectable or metastatic melanoma; n = 8) and 2A (advanced, recurrent, or metastatic HNSCC; n = 14), ORR was 87.5 and 42.9%; CR rate was 37.5 and 7.1%; unconfirmed CR rate was 0.0 and 7.1%; PR rate was 37.5 and 28.6%; unconfirmed PR rate was 12.5 and 0.0%; SD rate was 12.5 and 50.0%; DCR was 100.0 and 92.9%, respectively. In the efficacy evaluable set across cohorts 1A (n = 8) and 2A (n = 13), ORR was 87.5 and 46.2%; seven and eight patients respectively had &gt; 30% change from baseline in target lesion sum of diameters [ <ulink linkID=\"2567222\" linkType=\"Reference\">  2567222 </ulink>],</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In May 2021, a BLA for lifileucel for metastatic melanoma was expected in 1H22 [ <ulink linkID=\"2457363\" linkType=\"Reference\">  2457363 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Positive Outcome",
                "milestoneDate": "31-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, pre-BLA meeting was completed with the US FDA and agreed upon the clinical and safety dataset for BLA review [  <ulink linkID=\"2714601\" linkType=\"Reference\">  2714601 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In April 2022, BLA submission for lifileucel for the treatment of metastatic melanoma was expected by August 2022 [ <ulink linkID=\"2646126\" linkType=\"Reference\"> 2646126 </ulink>] </para>",
                "newMilestone": false
              },
              {
                "title": "Skip Phase",
                "status": "Granted",
                "milestoneDate": "25-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a rolling BLA submission was initiated for advanced unresectable or metastatic melanoma, based on data from the phase II (C-144-01) trial. No phase III trials had been conducted for this indication [ <ulink linkID=\"2726520\" linkType=\"Reference\"> 2726520 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "25-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, rolling BLA submission for US approval of the drug for the treatment of advanced (unresectable or metastatic) melanoma was initiated [ <ulink linkID=\"2726520\" linkType=\"Reference\"> 2726520 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, launch of the drug for the treatment of advanced melanoma was expected in that same year [ <ulink linkID=\"2839249\" linkType=\"Reference\"> 2839249 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, approval of the drug for the treatment of advanced melanoma was expected in that same year [ <ulink linkID=\"2839249\" linkType=\"Reference\"> 2839249 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, approval of the drug for the treatment of advanced melanoma was expected in that same year [ <ulink linkID=\"2839249\" linkType=\"Reference\"> 2839249 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "26-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the US FDA granted Priority Review for the treatment of advanced melanoma [ <ulink linkID=\"2956649\" linkType=\"Reference\"> 2956649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Other Outcome",
                "milestoneDate": "14-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a meeting with the US FDA was completed. At that time, the US FDA extended the PDUFA target action date to February 24, 2024, due to insufficient resources to review the BLA [ <ulink linkID=\"3195223\" linkType=\"Reference\"> 3195223 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2023, launch of the drug for the treatment of metastatic melanoma was expected later that year [ <ulink linkID=\"2871221\" linkType=\"Reference\"> 2871221 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "25-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the US FDA accepted the BLA, granted Priority Review and set a PDUFA target action date of November 25, 2023 [ <ulink linkID=\"2956649\" linkType=\"Reference\"> 2956649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "24-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA extended the PDUFA target action date to February 24, 2024, due to insufficient resources to review the BLA [ <ulink linkID=\"3195223\" linkType=\"Reference\"> 3195223 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2018",
            "endDate": "17-Oct-2028",
            "statusDate": "27-Apr-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2018",
                "endDate": "04-Feb-2025",
                "successPercentage": "15%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Feb-2025",
                "endDate": "06-Oct-2027",
                "successPercentage": "20%",
                "predictedDateL50": "10-Apr-2024",
                "predictedDateU50": "22-Oct-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Oct-2027",
                "endDate": "09-Sep-2028",
                "successPercentage": "79%",
                "predictedDateL50": "18-Aug-2026",
                "predictedDateU50": "08-Mar-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-May-2028",
                "predictedDateU50": "17-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Dec-2019",
            "endDate": "22-Jul-2028",
            "statusDate": "23-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Dec-2019",
                "endDate": "13-Nov-2024",
                "successPercentage": "18%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Nov-2024",
                "endDate": "06-Jun-2027",
                "successPercentage": "17%",
                "predictedDateL50": "20-Feb-2024",
                "predictedDateU50": "06-Jun-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jun-2027",
                "endDate": "05-Jun-2028",
                "successPercentage": "77%",
                "predictedDateL50": "27-Apr-2026",
                "predictedDateU50": "20-Oct-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Feb-2028",
                "predictedDateU50": "22-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Jan-2022",
                "notes": "In February 2020, a phase II trial (NCT04111510) in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies was expected to complete in January 2022 [<ulink linkType=\"Reference\" linkID=\"2245656\">2245656</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Aug-2018",
            "endDate": "19-Oct-2028",
            "statusDate": "17-Aug-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Aug-2018",
                "endDate": "22-Feb-2025",
                "successPercentage": "14%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Feb-2025",
                "endDate": "15-Sep-2027",
                "successPercentage": "11%",
                "predictedDateL50": "22-Feb-2024",
                "predictedDateU50": "05-Nov-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Sep-2027",
                "endDate": "10-Sep-2028",
                "successPercentage": "74%",
                "predictedDateL50": "06-Aug-2026",
                "predictedDateU50": "29-Jan-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-May-2028",
                "predictedDateU50": "19-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "05-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data from a phase II trial (NCT03610490) in patients with metastatic colorectal, pancreatic and ovarian cancers were presented. Grade 3 toxicities which were attributed to therapy included anemia (44%), febrile neutropenia (13%), hypophosphatemia (13%), hypotension (6%), neutropenia (6%) and thrombocytopenia (6%), and grade 4 were neutropenia (25%) and thrombocytopenia (75%). There were no responders; in colorectal (n = 8), pancreatic ductal adenocarcinoma (n = 5) and ovarian cancer (n = 3) patients, stable disease was achieved by three, one and two patients and progressive disease was seen in five, four and one patients, respectively [ <ulink linkID=\"2692218\" linkType=\"Reference\">  2692218 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Oct-2017",
            "endDate": "22-Dec-2024",
            "statusDate": "19-Oct-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "11-Oct-2017",
                "endDate": "19-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Oct-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "14-Nov-2024",
                "successPercentage": "74%",
                "predictedDateL50": "13-Nov-2022",
                "predictedDateU50": "15-Aug-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jul-2024",
                "predictedDateU50": "22-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "30-Nov-2020",
                "notes": "In November 2020, a potential registration-directed phase II study (NCT04614103; IOV-LUN-202) for LN-145 in patients with previously treated recurrent or metastatic NSCLC, without driver mutations, was expected to start later that month [<ulink linkType=\"Reference\" linkID=\"2359179\">2359179</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Skip Phase",
                "status": "Planned",
                "milestoneDate": "07-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive feedback was provided by FDA indicating that the design of the IOV-LUN-202 trial may be acceptable for accelerated approval of LN-145 for patients with advanced (unresectable or metastatic) NSCLC without EGFR, ROS or ALK mutations who had received one line of FDA-approved therapy and have progressed after chemotherapy and anti-PD-1 therapy [ <ulink linkID=\"3005410\" linkType=\"Reference\"> 3005410 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, additional data were reported from the phase II IOV-COM-202 (NCT03645928) study in patients with metastatic non-small-cell lung cancer (NSCLC) who enrolled in cohort 3B. Overall response rate (ORR) by investigator per RECIST 1.1 was 21.4% (n=28, one complete response and five partial responses) and the disease control rate (DCR) was 64.3% following treatment with LN-145 monotherapy, including two responders with PD-L1 negative tumors. Median duration of response was not reached at a median study follow up of 8.2 months [ <ulink linkID=\"2484632\" linkType=\"Reference\">  2484632 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In June 2021, further data from the phase II IOV-COM-202 (NCT03645928) study in patients with metastatic non-small-cell lung cancer (NSCLC) who enrolled in cohort 3B were expected in 2H21 [ <ulink linkID=\"2484632\" linkType=\"Reference\">  2484632 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2018, a phase II trial was initiated in the US to evaluate LN-145 and LN-144 in combination with pembrolizumab, in patients with advanced unresectable or metastatic melanoma, advanced squamous cell carcinoma of the head and neck, and metastatic non-small cell lung cancer. At that time, the study was due to complete in December 2024 [<ulink linkType=\"Reference\" linkID=\"2084932\">2084932</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-May-2019",
            "endDate": "25-Jul-2027",
            "statusDate": "13-May-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-May-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "40%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "16-Apr-2026",
                "successPercentage": "16%",
                "predictedDateL50": "17-Mar-2023",
                "predictedDateU50": "05-Jul-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Apr-2026",
                "endDate": "25-May-2027",
                "successPercentage": "72%",
                "predictedDateL50": "16-Apr-2025",
                "predictedDateU50": "10-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jan-2027",
                "predictedDateU50": "25-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, additional data were reported from the phase II IOV-COM-202 (NCT03645928) study in patients with metastatic non-small-cell lung cancer (NSCLC) who enrolled in cohort 3B. Overall response rate (ORR) by investigator per RECIST 1.1 was 21.4% (n=28, one complete response and five partial responses) and the disease control rate (DCR) was 64.3% following treatment with LN-145 monotherapy, including two responders with PD-L1 negative tumors. Median duration of response was not reached at a median study follow up of 8.2 months [ <ulink linkID=\"2484632\" linkType=\"Reference\">  2484632 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In June 2021, further data from the phase II IOV-COM-202 (NCT03645928) study in patients with metastatic non-small-cell lung cancer (NSCLC) who enrolled in cohort 3B were expected in 2H21 [ <ulink linkID=\"2484632\" linkType=\"Reference\">  2484632 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "08-Mar-2017",
            "endDate": "05-Oct-2027",
            "statusDate": "08-Mar-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "08-Mar-2017",
                "endDate": "23-Jan-2024",
                "successPercentage": "34%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Jan-2024",
                "endDate": "23-Sep-2026",
                "successPercentage": "20%",
                "predictedDateL50": "10-Feb-2023",
                "predictedDateU50": "19-Aug-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2026",
                "endDate": "28-Aug-2027",
                "successPercentage": "79%",
                "predictedDateL50": "05-Aug-2025",
                "predictedDateU50": "24-Feb-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-May-2027",
                "predictedDateU50": "05-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2018",
                "milestoneExtendedDate": "",
                "notes": "In January 2018, preliminary data from the phase II trial (NCT03083873) in patients with recurrent or metastatic head and neck squamous cell carcinoma were reported showing a reduction of at least 30% in tumor size in three of eight patients treated with the drug (partial response; PR) with an objective response rate (ORR) of 38%. These patients had previously received a median of four treatments with immunotherapies (either anti-PD-1 or anti-CTLA-4). At that time, enrollment was ongoing [<ulink linkType=\"Reference\" linkID=\"1999811\">1999811</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from the phase II trial (NCT03645928) in patients with head and neck squamous cell carcinoma receiving LN-145 in combination with pembrolizumab were reported showing an overall response rate of 44% [<ulink linkType=\"Reference\" linkID=\"2358936\">2358936</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, further data from a phase II trial (NCT03645928) in patients with unresectable or metastatic melanoma and metastatic HNSCC were presented. In the full analysis set across cohorts 1A (unresectable or metastatic melanoma; n = 8) and 2A (advanced, recurrent, or metastatic HNSCC; n = 14), ORR was 87.5 and 42.9%; CR rate was 37.5 and 7.1%; unconfirmed CR rate was 0.0 and 7.1%; PR rate was 37.5 and 28.6%; unconfirmed PR rate was 12.5 and 0.0%; SD rate was 12.5 and 50.0%; DCR was 100.0 and 92.9%, respectively. In the efficacy evaluable set across cohorts 1A (n = 8) and 2A (n = 13), ORR was 87.5 and 46.2%; seven and eight patients respectively had &gt; 30% change from baseline in target lesion sum of diameters [ <ulink linkID=\"2567222\" linkType=\"Reference\">  2567222 </ulink>],</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2018, a phase II trial was initiated in the US to evaluate LN-145 and LN-144 in combination with pembrolizumab, in patients with advanced unresectable or metastatic melanoma, advanced squamous cell carcinoma of the head and neck, and metastatic non-small cell lung cancer. At that time, the study was due to complete in December 2024 [<ulink linkType=\"Reference\" linkID=\"2084932\">2084932</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-May-2019",
            "endDate": "05-Jan-2028",
            "statusDate": "09-May-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-May-2019",
                "endDate": "23-Jan-2024",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Jan-2024",
                "endDate": "29-Sep-2026",
                "successPercentage": "22%",
                "predictedDateL50": "20-Feb-2023",
                "predictedDateU50": "12-Sep-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2026",
                "endDate": "04-Nov-2027",
                "successPercentage": "79%",
                "predictedDateL50": "09-Aug-2025",
                "predictedDateU50": "02-Mar-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Jun-2027",
                "predictedDateU50": "05-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, further data from a phase II trial (NCT03645928) in patients with unresectable or metastatic melanoma and metastatic HNSCC were presented. In the full analysis set across cohorts 1A (unresectable or metastatic melanoma; n = 8) and 2A (advanced, recurrent, or metastatic HNSCC; n = 14), ORR was 87.5 and 42.9%; CR rate was 37.5 and 7.1%; unconfirmed CR rate was 0.0 and 7.1%; PR rate was 37.5 and 28.6%; unconfirmed PR rate was 12.5 and 0.0%; SD rate was 12.5 and 50.0%; DCR was 100.0 and 92.9%, respectively. In the efficacy evaluable set across cohorts 1A (n = 8) and 2A (n = 13), ORR was 87.5 and 46.2%; seven and eight patients respectively had &gt; 30% change from baseline in target lesion sum of diameters [ <ulink linkID=\"2567222\" linkType=\"Reference\">  2567222 </ulink>],</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from the Cohort 3A from the phase II trial (NCT03645928) in solid tumors demonstrating 47% patients showed ORR in combination with pembrolizumab were reported [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, data from the phase II trial (NCT03645928) in solid tumors was expected later in that year [ <ulink linkID=\"2812115\" linkType=\"Reference\"> 2812115 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1057053",
              "name": "Iovance Biotherapeutics Inc"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Aug-2018",
            "endDate": "16-Dec-2028",
            "statusDate": "17-Aug-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Aug-2018",
                "endDate": "02-Mar-2025",
                "successPercentage": "19%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Mar-2025",
                "endDate": "01-Nov-2027",
                "successPercentage": "21%",
                "predictedDateL50": "25-Feb-2024",
                "predictedDateU50": "14-Nov-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Nov-2027",
                "endDate": "30-Oct-2028",
                "successPercentage": "89%",
                "predictedDateL50": "13-Sep-2026",
                "predictedDateU50": "03-Apr-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Oct-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jun-2028",
                "predictedDateU50": "16-Dec-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "05-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data from a phase II trial (NCT03610490) in patients with metastatic colorectal, pancreatic and ovarian cancers were presented. Grade 3 toxicities which were attributed to therapy included anemia (44%), febrile neutropenia (13%), hypophosphatemia (13%), hypotension (6%), neutropenia (6%) and thrombocytopenia (6%), and grade 4 were neutropenia (25%) and thrombocytopenia (75%). There were no responders; in colorectal (n = 8), pancreatic ductal adenocarcinoma (n = 5) and ovarian cancer (n = 3) patients, stable disease was achieved by three, one and two patients and progressive disease was seen in five, four and one patients, respectively [ <ulink linkID=\"2692218\" linkType=\"Reference\">  2692218 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "91145",
        "displayName": "bevacizumab biosimilar, Bio-Thera Solutions",
        "drugPrograms": [
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Dec-2018",
            "endDate": "",
            "statusDate": "24-Aug-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "06-Jul-2025",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "24-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Feb-2024",
                "predictedDateU50": "06-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jan-2021",
            "endDate": "",
            "statusDate": "28-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "06-Jul-2025",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "24-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Feb-2024",
                "predictedDateU50": "06-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jan-2021",
            "endDate": "",
            "statusDate": "28-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "09-Apr-2025",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "02-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jan-2024",
                "predictedDateU50": "09-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "16-Jun-2024",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Mar-2023",
                "predictedDateU50": "16-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021, the drug was expected to be approved in 2021 [<ulink linkType=\"Reference\" linkID=\"2418348\">2418348</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2020",
            "endDate": "",
            "statusDate": "30-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2020",
            "endDate": "",
            "statusDate": "30-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Nov-2020",
            "endDate": "",
            "statusDate": "25-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "25-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1084235",
              "name": "Bio-Thera Solutions Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jan-2021",
            "endDate": "",
            "statusDate": "28-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "93978",
        "displayName": "rituximab biosimilar, Dr Reddy's Laboratories",
        "drugPrograms": [
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "291",
              "name": "Rheumatoid arthritis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "08-Apr-2020",
            "endDate": "11-Jul-2025",
            "statusDate": "08-Apr-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "08-Apr-2020",
                "endDate": "18-Jun-2024",
                "successPercentage": "70%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Jun-2024",
                "endDate": "31-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jan-2024",
                "predictedDateU50": "18-Sep-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Feb-2025",
                "predictedDateU50": "11-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By July 2023, data were reported from a phase III trial (NCT04268771) for the treatment of rheumatoid arthritis [ <ulink linkID=\"3008808\" linkType=\"Reference\"> 3008808 </ulink>].  </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Feb-2019",
            "endDate": "22-Sep-2024",
            "statusDate": "12-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "01-Feb-2019",
                "endDate": "12-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2023",
                "endDate": "03-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Aug-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Apr-2024",
                "predictedDateU50": "22-Sep-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "12-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the BLA was accepted by the EMA for the treatment of follicle center lymphoma [ <ulink linkID=\"3008808\" linkType=\"Reference\"> 3008808 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Oct-2019",
            "endDate": "22-May-2025",
            "statusDate": "02-Oct-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Oct-2019",
                "endDate": "23-Apr-2024",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Apr-2024",
                "endDate": "13-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jan-2024",
                "predictedDateU50": "11-Aug-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2024",
                "predictedDateU50": "22-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Feb-2019",
            "endDate": "12-Aug-2024",
            "statusDate": "12-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "01-Feb-2019",
                "endDate": "12-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2023",
                "endDate": "05-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Mar-2024",
                "predictedDateU50": "12-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, a phase III (FLINTER) trial in follicular lymphoma was expected to complete in September 2020 [ <ulink linkID=\"2160574\" linkType=\"Reference\"> 2160574 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "12-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the BLA was accepted by the US FDA for the treatment of follicle center lymphoma [ <ulink linkID=\"3008808\" linkType=\"Reference\"> 3008808 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "97321",
        "displayName": "bevacizumab biosimilar, Samsung Bioepis",
        "drugPrograms": [
          {
            "company": {
              "id": "1071703",
              "name": "Samsung Bioepis Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "30-Sep-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2019",
            "endDate": "",
            "statusDate": "30-Sep-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "100235",
        "displayName": "penpulimab",
        "drugPrograms": [
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "131",
              "name": "Gastrointestinal tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Jun-2020",
            "endDate": "28-Sep-2027",
            "statusDate": "03-Jun-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Jun-2020",
                "endDate": "19-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Apr-2024",
                "endDate": "10-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "31-Dec-2023",
                "predictedDateU50": "19-Jul-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jun-2026",
                "endDate": "26-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "27-Jun-2025",
                "predictedDateU50": "15-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Mar-2027",
                "predictedDateU50": "28-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, a phase II trial of combination of AK-105 and anlotinib for gastrointestinal, urinary system and neuroendocrine tumors was planned to complete in May 2021 [ <ulink linkID=\"2231462\" linkType=\"Reference\">  2231462 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "738",
              "name": "Urinary tract tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Jun-2020",
            "endDate": "10-Sep-2027",
            "statusDate": "03-Jun-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Jun-2020",
                "endDate": "28-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Mar-2024",
                "endDate": "24-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "29-Dec-2023",
                "predictedDateU50": "08-Jun-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2026",
                "endDate": "08-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jun-2025",
                "predictedDateU50": "27-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Feb-2027",
                "predictedDateU50": "10-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, a phase II trial of combination of AK-105 and anlotinib for gastrointestinal, urinary system and neuroendocrine tumors was planned to complete in May 2021 [ <ulink linkID=\"2231462\" linkType=\"Reference\">  2231462 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, a phase II study (ChiCTR2200056732) was expected to be completed by September 2022 [ <ulink linkID=\"2629054\" linkType=\"Reference\">  2629054 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1128",
              "name": "Neuroendocrine tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Jun-2020",
            "endDate": "",
            "statusDate": "03-Jun-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Jun-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Sep-2021",
            "endDate": "01-Dec-2027",
            "statusDate": "15-Sep-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Sep-2021",
                "endDate": "20-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jul-2024",
                "endDate": "23-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "20-Apr-2024",
                "predictedDateU50": "31-Aug-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Aug-2026",
                "endDate": "30-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Sep-2025",
                "predictedDateU50": "26-Dec-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-May-2027",
                "predictedDateU50": "01-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Jul-2024",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, a phase II trial (NCT04952493) was expected to complete in July 2024 in patients  with local advanced or metastatic differentiated thyroid cancer [ <ulink linkID=\"2609966\" linkType=\"Reference\">  2609966 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2020",
            "endDate": "04-May-2027",
            "statusDate": "28-Dec-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Dec-2020",
                "endDate": "13-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Mar-2024",
                "endDate": "29-Jan-2026",
                "successPercentage": "95%",
                "predictedDateL50": "30-Dec-2023",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": "1.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jan-2026",
                "endDate": "05-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "10-Apr-2025",
                "predictedDateU50": "29-May-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Oct-2026",
                "predictedDateU50": "04-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an investigator-initiated, phase II trial (NCT05001971; ALTER-L041) of penpulimab combined with anlotinib in patients with sensitive relapsed small cell lung cancer was estimated to complete in December 2023 [ <ulink linkID=\"2518993\" linkType=\"Reference\">  2518993 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2019",
            "endDate": "07-Apr-2025",
            "statusDate": "11-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2019",
                "endDate": "11-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Aug-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "28-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "10-Aug-2023",
                "predictedDateU50": "09-Feb-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Sep-2024",
                "predictedDateU50": "07-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04344158) for hepatocellular carcinoma was expected to start in May 2020 [ <ulink linkID=\"2266613\" linkType=\"Reference\">  2266613 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive preliminary results of the phase Ib/II trial (NCT04172571) data cutoff date 14 January 2020 were to present at 2020 ASCO Annual Meeting, and data demonstrated good safety and tolerance of Penpulimab (200 mg Q3W) in combination with Anlotinib for HCC [ <ulink linkID=\"2280052\" linkType=\"Reference\">  2280052 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial for hepatocellular carcinoma was expected to complete in June 2021 [ <ulink linkID=\"2220940\" linkType=\"Reference\">  2220940 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2019, an NDA filing for cHL, NPC squamous NSCLC, non-squamous NSCLC and HCC was expected 1H20, 2H20, 1H21, 2H21 and 2H22, respectively in China [ <ulink linkID=\"2227518\" linkType=\"Reference\">  2227518 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04344158) for hepatocellular carcinoma was expected to complete in December 2024 [ <ulink linkID=\"2266613\" linkType=\"Reference\">  2266613 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2019",
            "endDate": "14-Mar-2026",
            "statusDate": "05-Aug-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2019",
                "endDate": "05-Aug-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2021",
                "endDate": "01-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Feb-2024",
                "predictedDateU50": "14-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, an NDA filing for cHL, NPC squamous NSCLC, non-squamous NSCLC and HCC was expected 1H20, 2H20, 1H21, 2H21 and 2H22, respectively in China [ <ulink linkID=\"2227518\" linkType=\"Reference\">  2227518 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the registrational phase II trial (NCT03866967) for third-line treatment of metastatic nasopharyngeal cancer met its primary endpoints [ <ulink linkID=\"2339642\" linkType=\"Reference\">  2339642 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive date from the registrational phase II trial (NCT03866967) for third-line treatment of metastatic nasopharyngeal cancer were reported [ <ulink linkID=\"2339642\" linkType=\"Reference\">  2339642 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021,an NDA for third-line treatment of nasopharyngeal cancer was expected in 1H21 [ <ulink linkID=\"2429572\" linkType=\"Reference\">  2429572 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "20-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, an implied trial approval was granted for advanced nasopharyngeal carcinoma in China [ <ulink linkID=\"2485826\" linkType=\"Reference\">  2485826 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "05-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an NDA for the third-line treatment of metastatic nasopharyngeal carcinoma was filed and accepted for review by the China NMPA [ <ulink linkID=\"2505415\" linkType=\"Reference\">  2505415 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive data from a phase II trial (NCT04736810) in 17 patients with metastatic nasopharyngeal carcinoma were presented. Across cohorts A (gemcitabine + cisplatin + penpulimab + anlotinib; n = 5), B (gemcitabine + cisplatin + penpulimab; n = 5) and C (gemcitabine + penpulimab + anlotinib; n = 7), the confirmed ORR was 80, 80 and 100%; CR was observed in 0, 20 and 14.3% of patients; PR was observed in 80, 60 and 85.7% of patients; stable disease was reported in 20, 20 and 0% of patients, respectively. Confirmed CR was achieved by one cohort C patient and all other had confirmed PR. Across cohorts A, B and C, serious AEs were reported in 28.6, 20 and 14.3% of patients, respectively [ <ulink linkID=\"2692042\" linkType=\"Reference\">  2692042 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "29-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, an implied trial approval was granted for AK-105 in combination with  <ulink linkID=\"84695\" linkType=\"Reference\">  catequentinib </ulink> for patients with advanced hepatocellular carcinoma who had not received prior systemic therapy in China [ <ulink linkID=\"2711502\" linkType=\"Reference\">  2711502 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Breakthrough Therapy",
            "startDate": "24-May-2021",
            "endDate": "",
            "statusDate": "24-May-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Jun-2020",
            "endDate": "15-May-2027",
            "statusDate": "03-Jun-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Jun-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "24-Jan-2026",
                "successPercentage": "95%",
                "predictedDateL50": "11-Sep-2023",
                "predictedDateU50": "20-Feb-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Jan-2026",
                "endDate": "12-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Feb-2025",
                "predictedDateU50": "30-May-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Oct-2026",
                "predictedDateU50": "15-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, positive interim data from a phase II trial (NCT04207463) in 15 patients with metastatic or advanced urothelial carcinoma were presented. The ORR was 33.3%, DCR was 80%, PR rate was 33.3%, and SD rate was 46.7%. The median PFS was 6.8 months and OS rate was 85.6%. Grade 3 TRAEs occurred in 40% of patients, including hypertension (20%), hand-foot syndrome (13.3%), mucositis oral, increased AST, and heart dysrhythmias (6.7% each). There was no grade 4 to 5 TRAEs. [ <ulink linkID=\"2748328\" linkType=\"Reference\">  2748328 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2021",
            "endDate": "30-Jun-2027",
            "statusDate": "05-Sep-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2021",
                "endDate": "29-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Mar-2024",
                "endDate": "11-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "26-Dec-2023",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Apr-2026",
                "endDate": "06-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-May-2025",
                "predictedDateU50": "13-Aug-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Dec-2026",
                "predictedDateU50": "30-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, a phase II trial (NCT05033587) in combination with anlotinib and radiotherapy in patients with glioblastoma was expected to complete in November 2023 [ <ulink linkID=\"2531163\" linkType=\"Reference\">  2531163 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Aug-2020",
            "endDate": "06-Sep-2025",
            "statusDate": "10-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Aug-2020",
                "endDate": "10-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-May-2024",
                "endDate": "30-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jan-2024",
                "predictedDateU50": "17-Jul-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Feb-2025",
                "predictedDateU50": "06-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, a phase III trial (NCT04385550) in patients with advanced gastric cancer was expected to complete in December 2023 [ <ulink linkID=\"2280140\" linkType=\"Reference\">  2280140 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Aug-2020",
            "endDate": "10-Sep-2025",
            "statusDate": "10-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Aug-2020",
                "endDate": "14-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-May-2024",
                "endDate": "02-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "09-Jan-2024",
                "predictedDateU50": "05-Aug-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Feb-2025",
                "predictedDateU50": "10-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, a phase III trial (NCT04385550) in patients with advanced gastro-oesophageal junction adenocarcinoma was expected to complete in December 2023 [ <ulink linkID=\"2280140\" linkType=\"Reference\">  2280140 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2022",
            "endDate": "26-Nov-2029",
            "statusDate": "01-Jun-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2022",
                "endDate": "01-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Jul-2026",
                "endDate": "10-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Feb-2026",
                "predictedDateU50": "25-Sep-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Aug-2028",
                "endDate": "23-Sep-2029",
                "successPercentage": "95%",
                "predictedDateL50": "04-Sep-2027",
                "predictedDateU50": "12-Dec-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-May-2029",
                "predictedDateU50": "26-Nov-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase II trial (NCT05493995) was expected to complete in December 2024 [ <ulink linkID=\"2716777\" linkType=\"Reference\">  2716777 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the phase II trial (NCT06051851) for metastatic pancreatic cancer was expected to complete in July 2026 [ <ulink linkID=\"3249582\" linkType=\"Reference\"> 3249582 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-May-2020",
            "endDate": "12-Sep-2027",
            "statusDate": "09-May-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-May-2020",
                "endDate": "08-May-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-May-2024",
                "endDate": "18-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "27-Dec-2023",
                "predictedDateU50": "04-Aug-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Jun-2026",
                "endDate": "17-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jul-2025",
                "predictedDateU50": "20-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Mar-2027",
                "predictedDateU50": "12-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, a phase II trial of combination of AK-105 and anlotinib for advanced advanced head, neck and chest cancer was planned to complete in May 2021 [ <ulink linkID=\"2230685\" linkType=\"Reference\">  2230685 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Opinion",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, primary endpoint (response rate) of a phase II study (NCT04203719) in patients with small-cell lung cancer after failure of platinum-based systemic chemotherapy was met. The objective response rate (ORR; primary endpoint) was 42.86%; ORR including unconfirmed partial response (PR) was 47.62%; disease control rate was 71.43%; complete response was achieved by one patient; PR and unconfirmed PR was achieved by eight and one patients, respectively; five patients had stable disease; four patients had progressive disease [ <ulink linkID=\"2469369\" linkType=\"Reference\">  2469369 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Opinion",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, interim results of a phase II study (NCT04203719) in patients with small-cell lung cancer after failure of platinum-based systemic chemotherapy were presented. The objective response rate (ORR; primary endpoint) was 42.86%; ORR including unconfirmed partial response (PR) was 47.62%; disease control rate was 71.43%; complete response was achieved by one patient; PR and unconfirmed PR was achieved by eight and one patients, respectively; five patients had stable disease; four patients had progressive disease [ <ulink linkID=\"2469369\" linkType=\"Reference\">  2469369 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1025425",
              "name": "Chia Tai Tianqing Pharmaceutical Group Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2019",
            "endDate": "",
            "statusDate": "30-Jun-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Sep-2021",
            "endDate": "01-Dec-2027",
            "statusDate": "15-Sep-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Sep-2021",
                "endDate": "20-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jul-2024",
                "endDate": "23-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2024",
                "predictedDateU50": "01-Sep-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Aug-2026",
                "endDate": "30-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Sep-2025",
                "predictedDateU50": "26-Dec-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-May-2027",
                "predictedDateU50": "01-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Jul-2024",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, a phase II trial (NCT04952493) was expected to complete in July 2024 in patients  with local advanced or metastatic differentiated thyroid cancer [ <ulink linkID=\"2609966\" linkType=\"Reference\">  2609966 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2020",
            "endDate": "14-Apr-2027",
            "statusDate": "28-Dec-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Dec-2020",
                "endDate": "04-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Mar-2024",
                "endDate": "20-Jan-2026",
                "successPercentage": "91%",
                "predictedDateL50": "30-Dec-2023",
                "predictedDateU50": "25-Apr-2024",
                "phaseDuration": "1.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jan-2026",
                "endDate": "17-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "01-Apr-2025",
                "predictedDateU50": "20-May-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Oct-2026",
                "predictedDateU50": "14-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an investigator-initiated, phase II trial (NCT05001971; ALTER-L041) of penpulimab combined with anlotinib in patients with sensitive relapsed small cell lung cancer was estimated to complete in December 2023 [ <ulink linkID=\"2518993\" linkType=\"Reference\">  2518993 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Nov-2018",
            "endDate": "23-Mar-2025",
            "statusDate": "11-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Nov-2018",
                "endDate": "11-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Aug-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "20-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "10-Aug-2023",
                "predictedDateU50": "09-Feb-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Sep-2024",
                "predictedDateU50": "23-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive preliminary results of the phase Ib/II trial (NCT04172571) data cutoff date 14 January 2020 were to present at 2020 ASCO Annual Meeting, and data demonstrated good safety and tolerance of Penpulimab (200 mg Q3W) in combination with Anlotinib for HCC [<ulink linkType=\"Reference\" linkID=\"2280052\">2280052</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In  January 2021, data from a phase III trial (NCT04344158) for penpulimab in combination with anlotinib as the first-line treatment of HCC were reported [<ulink linkType=\"Reference\" linkID=\"2395288\">2395288</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, a phase I/II trial for hepatocellular carcinoma was expected to complete in June 2021 [<ulink linkType=\"Reference\" linkID=\"2220940\">2220940</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2019, an NDA filing for cHL, NPC  squamous NSCLC, non-squamous NSCLC and HCC was expected 1H20, 2H20,  1H21, 2H21 and 2H22, respectively  in China [<ulink linkType=\"Reference\" linkID=\"2227518\">2227518</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Mar-2019",
            "endDate": "21-Jan-2026",
            "statusDate": "05-Aug-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Mar-2019",
                "endDate": "05-Aug-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2021",
                "endDate": "17-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2024",
                "predictedDateU50": "21-Jan-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, an NDA filing for cHL, NPC  squamous NSCLC, non-squamous NSCLC and HCC was expected 1H20, 2H20,  1H21, 2H21 and 2H22, respectively  in China [<ulink linkType=\"Reference\" linkID=\"2227518\">2227518</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the registrational phase II trial (NCT03866967) for third-line treatment of metastatic nasopharyngeal cancer met its primary endpoints [<ulink linkType=\"Reference\" linkID=\"2339642\">2339642</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, positive date from the registrational phase II trial (NCT03866967) for third-line treatment of metastatic nasopharyngeal cancer were reported [<ulink linkType=\"Reference\" linkID=\"2339642\">2339642</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, positive data from a phase II trial (NCT03866967) for metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy were reported [<ulink linkType=\"Reference\" linkID=\"2360131\">2360131</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "12-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, positive data from a phase II trial (NCT03866967) for metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy were reported. The confirmed objective response rate (ORR; primary endpoint) and the disease control rate (secondary endpoint) of patients (defined as patients who failed >/= 2 prior therapy and had an opportunity to be followed for at least 16 weeks and had measurable disease at baseline per response evaluation criteria in solid tumors version 1.1) was 27.0 and 49.5%, respectively [<ulink linkType=\"Reference\" linkID=\"2360131\">2360131</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, a phase II trial for metastatic nasopharyngeal carcinoma in China was expected to complete in December 2020 [<ulink linkType=\"Reference\" linkID=\"2128193\">2128193</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021,an NDA for third-line treatment of nasopharyngeal cancer was expected in 1H21   [<ulink linkType=\"Reference\" linkID=\"2429572\">2429572</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "05-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an NDA for third-line treatment of metastatic nasopharyngeal carcinoma was filed and accepted for review by the China NMPA [ <ulink linkID=\"2505415\" linkType=\"Reference\">  2505415 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive data from a phase II trial (NCT04736810) in 17 patients with metastatic nasopharyngeal carcinoma were presented. Across cohorts A (gemcitabine + cisplatin + penpulimab + anlotinib; n = 5), B (gemcitabine + cisplatin + penpulimab; n = 5) and C (gemcitabine + penpulimab + anlotinib; n = 7), the confirmed ORR was 80, 80 and 100%; CR was observed in 0, 20 and 14.3% of patients; PR was observed in 80, 60 and 85.7% of patients; stable disease was reported in 20, 20 and 0% of patients, respectively. Confirmed CR was achieved by one cohort C patient and all other had confirmed PR. Across cohorts A, B and C, serious AEs were reported in 28.6, 20 and 14.3% of patients, respectively [ <ulink linkID=\"2692042\" linkType=\"Reference\">  2692042 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Orphan Drug, Breakthrough Therapy",
            "startDate": "24-May-2021",
            "endDate": "",
            "statusDate": "24-May-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "24-May-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2021",
            "endDate": "26-Jun-2027",
            "statusDate": "05-Sep-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2021",
                "endDate": "25-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2024",
                "endDate": "07-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "23-Dec-2023",
                "predictedDateU50": "09-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Apr-2026",
                "endDate": "02-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "16-May-2025",
                "predictedDateU50": "09-Aug-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Dec-2026",
                "predictedDateU50": "26-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, a phase II trial (NCT05033587) in combination with anlotinib and radiotherapy in patients with glioblastoma was expected to complete in November 2023 [ <ulink linkID=\"2531163\" linkType=\"Reference\">  2531163 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Aug-2020",
            "endDate": "23-Aug-2025",
            "statusDate": "10-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "87%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Aug-2020",
                "endDate": "10-May-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-May-2024",
                "endDate": "22-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jan-2024",
                "predictedDateU50": "17-Jul-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Feb-2025",
                "predictedDateU50": "23-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Aug-2020",
            "endDate": "23-Aug-2025",
            "statusDate": "10-Aug-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "88%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Aug-2020",
                "endDate": "14-May-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-May-2024",
                "endDate": "23-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "09-Jan-2024",
                "predictedDateU50": "05-Aug-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2025",
                "predictedDateU50": "23-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2022",
            "endDate": "28-May-2028",
            "statusDate": "01-Jun-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2022",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2024",
                "endDate": "10-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Aug-2024",
                "predictedDateU50": "26-Mar-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Feb-2027",
                "endDate": "25-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "06-Mar-2026",
                "predictedDateU50": "14-Jun-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Nov-2027",
                "predictedDateU50": "28-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, a phase II trial (NCT05493995) was expected to complete in December 2024 [ <ulink linkID=\"2716777\" linkType=\"Reference\">  2716777 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1075032",
              "name": "Akeso Biopharma Inc"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Sep-2019",
            "endDate": "",
            "statusDate": "02-Sep-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Sep-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "101768",
        "displayName": "afamitresgene autoleucel",
        "drugPrograms": [
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "09-May-2029",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "09-Jan-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "09-Jan-2024",
                "endDate": "07-Jan-2026",
                "successPercentage": "13%",
                "predictedDateL50": "26-Apr-2023",
                "predictedDateU50": "15-Sep-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Jan-2026",
                "endDate": "04-Apr-2028",
                "successPercentage": "28%",
                "predictedDateL50": "31-Dec-2024",
                "predictedDateU50": "05-Jun-2026",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2028",
                "endDate": "31-Mar-2029",
                "successPercentage": "94%",
                "predictedDateL50": "12-Apr-2027",
                "predictedDateU50": "23-Aug-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Mar-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Dec-2028",
                "predictedDateU50": "09-May-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, initial data from the phase I trial (NCT03132922) were reported. Out of the six patients treated, best response was best response was stable disease and progressive disease in four and two patients, respectively. One 1 patient with stable disease had an overall 27% reduction of target lesions observed at week 6 [<ulink linkType=\"Reference\" linkID=\"2085409\">2085409</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "By November 2018, from the phase I trial (NCT03132922) a favorable review of safety data by the SRC from the third dose cohort of patients (treated with a target dose of 5 billion cells; range 1.2 to 10 billion) had been received, showing that this dose was also tolerable, with no dose limiting toxicities. At that time, the study was to move into the expansion phase, to treat patients with up to 10 billion cells, without a pre-determined stagger, across a broad range of tumor types [<ulink linkType=\"Reference\" linkID=\"2091275\">2091275</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, further data from phase I trial (NCT03132922) in patients with relapsed/refractory metastatic solid tumors including synovial sarcoma (SS), ovarian cancer and head and neck cancer were published [ <ulink linkID=\"2805490\" linkType=\"Reference\">  2805490 </ulink>], [ <ulink linkID=\"2809430\" linkType=\"Reference\">  2809430 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2016",
            "endDate": "",
            "statusDate": "21-Apr-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "21-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "2447",
              "name": "Liposarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2018",
            "endDate": "29-Jun-2025",
            "statusDate": "25-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "9%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "27-Apr-2018",
                "endDate": "25-Jul-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "09-Jun-2024",
                "successPercentage": "26%",
                "predictedDateL50": "16-Feb-2023",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2024",
                "endDate": "20-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "11-Dec-2023",
                "predictedDateU50": "28-Oct-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Jan-2025",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, initial data from the phase I trial (NCT03132922) were reported. Out of the six patients treated, best response was best response was stable disease and progressive disease in four and two patients, respectively. One 1 patient with stable disease had an overall 27% reduction of target lesions observed at week 6 [<ulink linkType=\"Reference\" linkID=\"2085409\">2085409</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In Febraury 2021,  preliminary data from the  phase II trial in patients with myxoid/round cell liposarcoma and synovial sarcoma were expected  in June 2021 [<ulink linkType=\"Reference\" linkID=\"2180728\">2412512</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, interim analysis data of a phase II study (NCT04044768) in 37 patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma were presented [ <ulink linkID=\"2469774\" linkType=\"Reference\">  2469774 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were reported for the phase II study (NCT04044768) in 37 patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma which showed that the trial met its co-primary endpoints. Of the 37 evaluable patients, two patients achieved a complete response in synovial carcinoma; the best overall response rate was 39.4% [ <ulink linkID=\"2469774\" linkType=\"Reference\">  2469774 </ulink>].      </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, positive results were reported from phase II study (NCT04044768; ADP 0044-002; SPEARHEAD‑1) in patients with advanced (metastatic or inoperable) synovial sarcoma or MRCLS [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, BLA filing for synovial sarcoma and MRCLS was expected in 2022, based on data from SPEARHEAD-1 trial [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "14-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, it was reported that the SPEARHEAD-1 phase II trial (NCT04044768) met its primary endpoint [  <ulink linkID=\"2631675\" linkType=\"Reference\">  2631675 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "2447",
              "name": "Liposarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Jul-2019",
            "endDate": "15-Aug-2027",
            "statusDate": "25-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "37%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "01-May-2026",
                "successPercentage": "29%",
                "predictedDateL50": "16-Feb-2023",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-May-2026",
                "endDate": "14-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Apr-2025",
                "predictedDateU50": "18-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jan-2027",
                "predictedDateU50": "15-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In Febraury 2021,  preliminary data from the  phase II trial in patients with myxoid/round cell liposarcoma and synovial sarcoma were expected  in June 2021 [<ulink linkType=\"Reference\" linkID=\"2180728\">2412512</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, interim analysis data of a phase II study (NCT04044768) in 37 patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma were presented [ <ulink linkID=\"2469774\" linkType=\"Reference\">  2469774 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive data were reported for the phase II study (NCT04044768) in 37 patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma which showed that the trial met its co-primary endpoints. Of the 37 evaluable patients, two patients achieved a complete response in synovial carcinoma; the best overall response rate was 39.4% [ <ulink linkID=\"2469774\" linkType=\"Reference\">  2469774 </ulink>].      </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, positive results were reported from phase II study (NCT04044768; ADP 0044-002; SPEARHEAD‑1) in patients with advanced (metastatic or inoperable) synovial sarcoma or MRCLS [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "14-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, it was reported that the SPEARHEAD-1 phase II trial (NCT04044768) met its primary endpoint [ <ulink linkID=\"2631675\" linkType=\"Reference\"> 2631675 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Regenerative Medicine Advanced Therapy",
            "startDate": "27-Apr-2018",
            "endDate": "09-Jan-2024",
            "statusDate": "23-Dec-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "27-Apr-2018",
                "endDate": "25-Jul-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2019",
                "endDate": "23-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Dec-2022",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Nov-2023",
                "predictedDateU50": "09-Jan-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, initial data from the phase I trial (NCT03132922) were reported. Out of the six patients treated, best response was best response was stable disease and progressive disease in four and two patients, respectively. One 1 patient with stable disease had an overall 27% reduction of target lesions observed at week 6 [<ulink linkType=\"Reference\" linkID=\"2085409\">2085409</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "By November 2018, from the phase I trial (NCT03132922) a favorable review of safety data by the SRC from the third dose cohort of patients (treated with a target dose of 5 billion cells; range 1.2 to 10 billion) had been received, showing that this dose was also tolerable, with no dose limiting toxicities. At that time, the study was to move into the expansion phase, to treat patients with up to 10 billion cells, without a pre-determined stagger, across a broad range of tumor types [<ulink linkType=\"Reference\" linkID=\"2091275\">2091275</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, data from an expansion cohort were reported [<ulink linkType=\"Reference\" linkID=\"2148335\">2148335</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "26-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, the FDA granted the product Orphan designation for treatment of soft tissue sarcoma [<ulink linkType=\"Reference\" linkID=\"2190010\">2190010</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regenerative Medicine Advanced Therapy",
                "status": "Granted",
                "milestoneDate": "27-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "By February 2020, the US FDA had granted the program Regenerative Medicine Advanced Therapy designation for synovial sarcoma [<ulink linkType=\"Reference\" linkID=\"2249780\">2249780</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2020, 12-month durability data from a phase I study (NCT03132922) in patients with synovial sarcoma were expected in the second half of 2020 [ <ulink linkID=\"2249780\" linkType=\"Reference\">  2249780 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "19-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, positive durability, safety and translational data from a phase I study (<ulink linkType=\"Protocol\" linkID=\"297171\">NCT03132922</ulink>) in patients with synovial sarcoma were reported [<ulink linkType=\"Reference\" linkID=\"2249780\">2364526</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In Febraury 2021, preliminary data from the  phase II trial in patients with myxoid/round cell liposarcoma and synovial sarcoma were expected  in June 2021 [<ulink linkType=\"Reference\" linkID=\"2180728\">2412512</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, positive results were reported from phase II study (NCT04044768; ADP 0044-002; SPEARHEAD‑1) in patients with advanced (metastatic or inoperable) synovial sarcoma or MRCLS [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, BLA filing for synovial sarcoma and MRCLS was expected in 2022, based on data from SPEARHEAD-1 trial [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In August 2020, launch in the US was expected in 2022 for the treatment of sarcoma [<ulink linkType=\"Reference\" linkID=\"2307135\">2307135</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "14-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, it was reported that the SPEARHEAD-1 phase II trial (NCT04044768) met its primary endpoint [  <ulink linkID=\"2631675\" linkType=\"Reference\">  2631675 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In March 2022, the BLA filling for synovial sarcoma was expected to be filed in the fourth quarter of 2022 [ <ulink linkID=\"2631675\" linkType=\"Reference\">  2631675 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "23-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, rolling BLA submission was initiated seeking US approval for use as a single-dose regimen for the treatment of synovial sarcoma, based on positive data from the  phase II SPEARHEAD‑1 trial [ <ulink linkID=\"2798587\" linkType=\"Reference\">  2798587 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Skip Phase",
                "status": "Granted",
                "milestoneDate": "23-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a rolling BLA submission was initiated seeking US approval for use as a single-dose regimen for the treatment of synovial sarcoma, based on positive data from the  phase II SPEARHEAD‑1 trial. No phase III trials have been conducted for this indication [ <ulink linkID=\"2798587\" linkType=\"Reference\">  2798587 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2022, company planned to launch the drug in the US in 2023 [  <ulink linkID=\"2678076\" linkType=\"Reference\">  2678076  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, further data from phase I trial (NCT03132922) in patients with relapsed/refractory metastatic solid tumors including synovial sarcoma (SS), ovarian cancer and head and neck cancer were published [ <ulink linkID=\"2805490\" linkType=\"Reference\">  2805490 </ulink>], [ <ulink linkID=\"2809430\" linkType=\"Reference\">  2809430 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, PRIME",
            "startDate": "25-Jul-2019",
            "endDate": "21-Feb-2027",
            "statusDate": "25-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "23-Jan-2026",
                "successPercentage": "91%",
                "predictedDateL50": "25-Apr-2023",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Jan-2026",
                "endDate": "12-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Feb-2025",
                "predictedDateU50": "28-May-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Sep-2026",
                "predictedDateU50": "21-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "23-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, the COMP adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas [<ulink linkType=\"Reference\" linkID=\"2271352\">2271352</ulink>], [<ulink linkType=\"Reference\" linkID=\"2278914\">2278914</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PRIME",
                "status": "Granted",
                "milestoneDate": "23-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, the European Medicines Agency (EMA) had granted access to the PRIME initiative to the company for ADP-A2M4 for the treatment of synovial sarcoma [<ulink linkType=\"Reference\" linkID=\"2303762\">2303762</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "06-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "By August 2020, the EMA had granted Orphan Drug Designation for ADP-A2M4 for the treatment of advanced soft tissue sarcomas [<ulink linkType=\"Reference\" linkID=\"2307135\">2307135</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In Febraury 2021, preliminary data from the  phase II trial in patients with myxoid/round cell liposarcoma and synovial sarcoma were expected  in June 2021 [<ulink linkType=\"Reference\" linkID=\"2180728\">2412512</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, positive results were reported from phase II study (NCT04044768; ADP 0044-002; SPEARHEAD‑1) in patients with advanced (metastatic or inoperable) synovial sarcoma or MRCLS [ <ulink linkID=\"2565418\" linkType=\"Reference\">  2565418 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "14-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, it was reported that the SPEARHEAD-1 phase II trial (NCT04044768) met its primary endpoint [  <ulink linkID=\"2631675\" linkType=\"Reference\">  2631675 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1047486",
              "name": "Adaptimmune Therapeutics plc"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jul-2020",
            "endDate": "27-Nov-2027",
            "statusDate": "02-Jul-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Jul-2020",
                "endDate": "22-Jul-2024",
                "successPercentage": "10%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Jul-2024",
                "endDate": "24-Nov-2026",
                "successPercentage": "33%",
                "predictedDateL50": "19-Jan-2024",
                "predictedDateU50": "19-Dec-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Nov-2026",
                "endDate": "23-Oct-2027",
                "successPercentage": "94%",
                "predictedDateL50": "19-Nov-2025",
                "predictedDateU50": "17-Apr-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Jul-2027",
                "predictedDateU50": "27-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, further data from phase I trial (NCT03132922) in patients with relapsed/refractory metastatic solid tumors including synovial sarcoma (SS), ovarian cancer and head and neck cancer were published [ <ulink linkID=\"2805490\" linkType=\"Reference\">  2805490 </ulink>], [ <ulink linkID=\"2809430\" linkType=\"Reference\">  2809430 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "102625",
        "displayName": "BT-595",
        "drugPrograms": [
          {
            "company": {
              "id": "13737",
              "name": "Biotest AG"
            },
            "indication": {
              "id": "504",
              "name": "Immune deficiency"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Oct-2016",
            "endDate": "08-Aug-2024",
            "statusDate": "30-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "94%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Oct-2016",
                "endDate": "30-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Jun-2023",
                "endDate": "29-Jun-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Jun-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Apr-2024",
                "predictedDateU50": "08-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "By June 2023, Biologics License Application (BLA) had been submitted to US Food and Drug Administration (FDA) for the polyspecific immunoglobulin, Yimmugo (IgG Next Generation) [ <ulink linkID=\"3038110\" linkType=\"Reference\"> 3038110 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned",
                "milestoneDate": "29-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA's decision for BLA/marketing authorization application for PID was expected on June 29, 2024 [ <ulink linkID=\"3102798\" linkType=\"Reference\"> 3102798 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned",
                "milestoneDate": "29-Jun-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA's decision for BLA/marketing authorization application for PID was expected on June 29, 2024 [ <ulink linkID=\"3102798\" linkType=\"Reference\"> 3102798 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "106247",
        "displayName": "trastuzumab biosimilar, EirGenix",
        "drugPrograms": [
          {
            "company": {
              "id": "1099975",
              "name": "EirGenix Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2016",
            "endDate": "04-May-2024",
            "statusDate": "22-Dec-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2016",
                "endDate": "16-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2018",
                "endDate": "22-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Dec-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jun-2023",
                "predictedDateU50": "04-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-May-2017",
                "milestoneExtendedDate": "",
                "notes": "In May 2017, the phase I study met its primary endpoint [<ulink linkType=\"Reference\" linkID=\"2109472\">2109472</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In April 2019, completion of primary endpoint analyis in the phase III trial in breast cancer in the US, Taiwan, South Africa, India, Colombia, Chile and in several European countrieswas expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2146165\">2146165</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In January 2019, the phase III trial to compare the safety and efficacy of EG-12014 with trastuzumab was expected to complete in July 2021 [<ulink linkType=\"Reference\" linkID=\"2109104\">2109104</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "22-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a MAA was submitted to the EMA for the biosimilar trastuzumab for HERs-positive breast and metastatic gastric cancers [ <ulink linkID=\"2588024\" linkType=\"Reference\">  2588024 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "18-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, EMA granted positive CHMP opinion to the drug for the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers [ <ulink linkID=\"3199381\" linkType=\"Reference\"> 3199381 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1099975",
              "name": "EirGenix Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Oct-2018",
            "endDate": "09-Jan-2025",
            "statusDate": "16-Oct-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "29-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "22-Sep-2023",
                "predictedDateU50": "24-Jan-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Aug-2024",
                "predictedDateU50": "09-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In April 2019, completion of primary endpoint analyis in the phase III trial in breast cancer in the US, Taiwan, South Africa, India, Colombia, Chile and in several European countrieswas expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2146165\">2146165</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In January 2019, the phase III trial to compare the safety and efficacy of EG-12014 with trastuzumab was expected to complete in July 2021 [<ulink linkType=\"Reference\" linkID=\"2109104\">2109104</ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1099975",
              "name": "EirGenix Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Oct-2018",
            "endDate": "07-Aug-2024",
            "statusDate": "18-Dec-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2018",
                "endDate": "18-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Dec-2021",
                "endDate": "08-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Dec-2023",
                "predictedDateU50": "07-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In April 2019, completion of primary endpoint analyis in the phase III trial in breast cancer in the US, Taiwan, South Africa, India, Colombia, Chile and in several European countrieswas expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2146165\">2146165</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, top-line data from the phase III trial (NCT03433313) for HER2-positive breast cancer were reported and the trial met the primary endpoint [<ulink linkType=\"Reference\" linkID=\"2426176\">2426176</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In January 2019, the phase III trial to compare the safety and efficacy of EG-12014 with trastuzumab was expected to complete in July 2021 [<ulink linkType=\"Reference\" linkID=\"2109104\">2109104</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "18-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, Biologics License Application (BLA) was submitted to the US FDA for breast cancer[ <ulink linkID=\"2586373\" linkType=\"Reference\">  2586373 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1099975",
              "name": "EirGenix Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2016",
            "endDate": "25-Mar-2024",
            "statusDate": "22-Dec-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2016",
                "endDate": "22-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Dec-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jul-2023",
                "predictedDateU50": "25-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-May-2017",
                "milestoneExtendedDate": "",
                "notes": "In May 2017, the phase I study met its primary endpoint [<ulink linkType=\"Reference\" linkID=\"2109472\">2109472</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "22-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a MAA was submitted to the EMA for the biosimilar trastuzumab for HERs-positive breast and metastatic gastric cancers [ <ulink linkID=\"2588024\" linkType=\"Reference\">  2588024 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "18-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, EMA granted positive CHMP opinion to the drug for the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers [ <ulink linkID=\"3199381\" linkType=\"Reference\"> 3199381 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1099975",
              "name": "EirGenix Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Dec-2021",
            "endDate": "17-Jun-2024",
            "statusDate": "20-Dec-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "20-Dec-2021",
                "endDate": "14-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Dec-2023",
                "predictedDateU50": "17-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "106283",
        "displayName": "trastuzumab biosimilar, Tanvex BioPharma",
        "drugPrograms": [
          {
            "company": {
              "id": "1147974",
              "name": "Tanvex BioPharma Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe(HU)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jun-2018",
            "endDate": "01-Feb-2025",
            "statusDate": "28-Jun-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Jun-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "12-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "13-Jul-2023",
                "predictedDateU50": "08-Apr-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Aug-2024",
                "predictedDateU50": "01-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In June 2018, a phase III trial was expected to complete in December 2020 [<ulink linkType=\"Reference\" linkID=\"2256486\">2256486</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In October 2020, the phase III data were expected in 1Q21 [<ulink linkType=\"Reference\" linkID=\"2345931\">2345931</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, positive topline results from phase III trial (<ulink linkType=\"Protocol\" linkID=\"342952\">NCT03556358</ulink>) in patients with HER2 positive early breast cancer demonstrating  therapeutic equivalence were reported [<ulink linkType=\"Reference\" linkID=\"2411623\">2411623</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "HU",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1147974",
              "name": "Tanvex BioPharma Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Aug-2021",
            "endDate": "22-Aug-2024",
            "statusDate": "03-Aug-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "03-Aug-2021",
                "endDate": "21-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "22-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1147974",
              "name": "Tanvex BioPharma Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Aug-2021",
            "endDate": "",
            "statusDate": "03-Aug-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "03-Aug-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "137795",
        "displayName": "HND-033",
        "drugPrograms": [
          {
            "company": {
              "id": "1048449",
              "name": "Handa Pharmaceuticals Inc"
            },
            "indication": {
              "id": "651",
              "name": "Cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Sep-2022",
            "endDate": "08-Feb-2024",
            "statusDate": "23-Sep-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2022",
                "endDate": "09-Jan-2024",
                "successPercentage": "21%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Dec-2023",
                "predictedDateU50": "08-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "28-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, an CRL of BLA for the drug was received in the US [ <ulink linkID=\"2935126\" linkType=\"Reference\"> 2935126 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1048449",
              "name": "Handa Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1728",
              "name": "Acute lymphoblastic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "23-Sep-2022",
            "endDate": "11-Feb-2024",
            "statusDate": "23-Sep-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "22%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2022",
                "endDate": "12-Jan-2024",
                "successPercentage": "22%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Dec-2023",
                "predictedDateU50": "11-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "03-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, the US FDA granted orphan designation to HND-033 for the treatment of acute lymphoblastic leukemia [ <ulink linkID=\"2770400\" linkType=\"Reference\"> 2770400 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "04-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022,the US FDA granted orphan drug designation to HND-033 for the treatment of AAL[ <ulink linkID=\"2768092\" linkType=\"Reference\">  2768092 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "28-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, an CRL of BLA for the drug was received in the US [ <ulink linkID=\"2935126\" linkType=\"Reference\"> 2935126 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1048449",
              "name": "Handa Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1735",
              "name": "Chronic myelocytic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "23-Sep-2022",
            "endDate": "11-Feb-2024",
            "statusDate": "23-Sep-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "22%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2022",
                "endDate": "12-Jan-2024",
                "successPercentage": "22%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Dec-2023",
                "predictedDateU50": "11-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "28-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, an CRL of BLA for the drug was received in the US [ <ulink linkID=\"2935126\" linkType=\"Reference\"> 2935126 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "145468",
        "displayName": "dasatinib hydrate",
        "drugPrograms": [
          {
            "company": {
              "id": "1034008",
              "name": "Nanocopoeia Inc"
            },
            "indication": {
              "id": "1728",
              "name": "Acute lymphoblastic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "27-Jan-2022",
            "endDate": "",
            "statusDate": "27-Jan-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "27-Jan-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "149177",
        "displayName": "paclitaxel (albumin-bound particles, injectable suspension, cancer), Teva Pharmaceuticals",
        "drugPrograms": [
          {
            "company": {
              "id": "20348",
              "name": "Teva Pharmaceutical Industries Ltd"
            },
            "indication": {
              "id": "936",
              "name": "Kaposis sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2021",
            "endDate": "",
            "statusDate": "30-Sep-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20348",
              "name": "Teva Pharmaceutical Industries Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2021",
            "endDate": "",
            "statusDate": "30-Sep-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20348",
              "name": "Teva Pharmaceutical Industries Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2021",
            "endDate": "",
            "statusDate": "30-Sep-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20348",
              "name": "Teva Pharmaceutical Industries Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2021",
            "endDate": "",
            "statusDate": "30-Sep-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      }
    ]
  }